10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

[X]	Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
	For the quarterly period ended September 30, 2016
[ ]	Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934
	For the transition period  to  __________
	Commission File Number:000-54767

Rich Pharmaceuticals, Inc.

(Exact name of Registrant as specified in its charter)

Nevada	46-3259117
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)

9595 Wilshire Blvd., Suite 900

Beverly Hills, California 90212

(Address of principal executive offices)

(424) 230-7001

(Registrant’s telephone number)

_____________________________________________________________

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the issuer was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days [X] Yes [ ] No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.

[ ] Large accelerated filer Accelerated filer	[ ] Non-accelerated filer
[X] Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). [] Yes [X] No

The number of shares outstanding of common stock as of November 3, 2016 was 960,815,966. 

	TABLE OF CONTENTS	Page
PART I - FINANCIAL INFORMATION
Item 1:	Financial Statements	3
Item 2:	Management’s Discussion and Analysis of Financial Condition and Results of Operations	4
Item 3:	Quantitative and Qualitative Disclosures About Market Risk	5
Item 4:	Controls and Procedures	5
PART II - OTHER INFORMATION
Item 1:	Legal Proceedings	6
Item 1A:	Risk Factors	6
Item 2:	Unregistered Sales of Equity Securities and Use of Proceeds	11
Item 3:	Defaults Upon Senior Securities	11
Item 4:	Mine Safety Disclosures	11
Item 5:	Other Information	11
Item 6:	Exhibits	11

Unless otherwise indicated, in this Form 10-Q, references to “we,” “our,” “us,” the “Company,” or the “Registrant” refer to Rich Pharmaceuticals Inc., a Nevada corporation.

FORWARD-LOOKING STATEMENTS

This Report on Form 10-Q contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995.  Reference is made in particular to the description of our plans and objectives for future operations, assumptions underlying such plans and objectives, and other forward-looking statements included in this report.  Such statements may be identified by the use of forward-looking terminology such as “may,” “will,” “expect,” “believe,” “estimate,” “anticipate,” “intend,” “continue,” or similar terms, variations of such terms or the negative of such terms.  Such statements are based on management’s current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements.  Such statements address future events and conditions concerning, among others, capital expenditures, earnings, litigation, regulatory matters, liquidity and capital resources, and accounting matters.  Actual results in each case could differ materially from those anticipated in such statements by reason of factors such as future economic conditions, changes in consumer demand, legislative, regulatory and competitive developments in markets in which we operate, results of litigation, and other circumstances affecting anticipated revenues and costs. You should not place undue reliance on these forward looking statements.

The forward-looking statements made in this report on Form 10-Q relate only to events or information as of the date on which the statements are made in this report on Form 10-Q.  Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.  You should read this report and the documents that we reference in this report, including documents referenced by incorporation, completely and with the understanding that our actual future results may be materially different from what we anticipate.

2

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

Condensed Balance Sheets (Unaudited) as of September 30, 2016 and March 31, 2016	F – 1
Condensed Statements of Operations (Unaudited) for the three and six months ended September 30, 2016 and 2015	F – 2
Condensed Statements of Cash Flows (Unaudited) for the six months ended September 30, 2016 and 2015	F – 3
Notes to Condensed Financial Statements (Unaudited)	F – 4 – F – 21

3

RICH PHARMACEUTICALS, INC.

CONDENSED BALANCE SHEETS (UNAUDITED)

	September 30, 2016			March 31, 2016
ASSETS
Current Assets
Cash and equivalents	$	—		$	—
Prepaid expenses		—			2,800
Total Current Assets		—			2,800
Property and equipment, net		2,869			3,731
TOTAL ASSETS	$	2,869		$	6,531
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current Liabilities
Bank overdraft	$	2,148		$	2,948
Accounts payable		350,730			1,139,431
Accrued expenses		761,111			530,150
Due to related parties		39,100			76,913
Note payable		900,000			—
Convertible notes payable, net of debt discount		437,428			201,879
Derivative liabilities		270,531			446,912
Total Current Liabilities		2,761,048			2,398,233
Long-term Liabilities
Convertible notes payable, net of debt discount		—			—
Derivative liabilities		—			—
Total Long-term Liabilities		—			—
Total Liabilities		2,761,048			2,398,233
Stockholders’ Deficit
Preferred stock, $.001 par value, 10,000,000 shares authorized, 6,000,000 shares issued and outstanding, respectively		6,000			6,000
Common stock, $0.001 par value, 4,000,000,000 shares authorized, 640,739,418 and 216,364,262 shares issued and outstanding,		640,736			216,364
Additional paid-in capital		6,243,408			6,589,374
Accumulated deficit		(9,648,323	)		(9,203,440	)
Total Stockholders’ Deficit		(2,758,179	)		(2,391,702	)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	2,869		$	6,531

See accompanying notes to financial statements.

F-1

RICH PHARMACEUTICALS, INC.

CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) 

	Three months ended September 30, 2016			Three months ended September 30, 2015			Six months ended September 30, 2016			Six months ended September 30, 2015
REVENUES	$	—		$	—		$	—		$	—
OPERATING EXPENSES
Consulting expenses		5,850			—			16,075			6,000
Office expenses		35,472			25,140			70,046			45,894
Depreciation expense		431			118			862			237
Wages and taxes		96,001			91,071			191,956			182,793
Professional fees		34,158			26,338			88,401			92,285
Regulatory fees		2,686			15,580			9,529			17,249
Research and development		—			2,000			—			9,000
Stock-based compensation		—			62,301			—			192,392
Travel, meals and entertainment		8,197			11,980			21,403			14,592
TOTAL OPERATING EXPENSES		182,795			234,528			398,272			560,442
LOSS FROM OPERATIONS		(182,795	)		(234,528	)		(398,272	)		(560,442	)
OTHER INCOME (EXPENSE)
Amortization of debt discount		(25,786	)		(101,837	)		(72,360	)		(270,988	)
Change in value of derivative liability		51,683			180,446			168,454			230,186
Derivative expense		—			(142,073	)		—			(335,244	)
Interest expense		(109,466	)		(11,082	)		(142,475	)		(20,255	)
Interest expense – related party		(155	)		(150	)		(230	)		(224	)
		(83,724	)		(74,696	)		(46,611	)		(396,525	)
LOSS BEFORE PROVISION FOR INCOME TAXES		(266,519	)		(309,224	)		(444,883	)		(956,967	)
PROVISION FOR INCOME TAXES		—			—			—			—
NET LOSS	$	(266,519	)	$	(309,224	)	$	(444,883	)	$	(956,697	)
NET LOSS PER SHARE: BASIC AND DILUTED	$	(0.00	)	$	(0.01	)	$	(0.00	)	$	(0.02	)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: BASIC AND DILUTED		461,006,135			35,569,186			398,719,073			56,827,068

See accompanying notes to financial statements. 

F-2

RICH PHARMACEUTICALS, INC.

CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)

FOR THE SIX MONTHS ENDED SEPTEMBER 30, 2016 AND 2015

	Six months ended September 30, 2016			Six months ended September 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss for the period	$	(444,883	)	$	(956,967	)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expense		863			236
Amortization of debt discount		72,360			270,988
Change in value of derivative liability		(168,454	)		(230,186	)
Derivative expense		—			335,244
Interest converted into stock		5,416			—
Warrants issued for services		—			13,259
Stock-based compensation		—			192,392
Changes in operating assets and liabilities:
Decrease in prepaid expenses		2,800			5,485
Increase (decrease) in bank overdraft		(800	)		484
Increase (decrease) in accounts payable		111,299			531
Increase in accrued expenses		230,961			137,398
Net Cash Used by Operating Activities		(190,438	)		(231,136	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Loans received (repaid) from/to related parties		(37,812	)		30,417
Proceeds from sale of common stock and warrants		—			50,873
Proceeds from issuance of convertible notes payable		228,250			133,954
Net Cash Provided by Financing Activities		190,438			215,244
Net Increase (Decrease) in Cash and Cash Equivalents		—			(15,892	)
Cash and cash equivalents, beginning of period		—			15,892
Cash and cash equivalents, end of period	$	—		$	—
SUPPLEMENTAL CASH FLOW INFORMATION:
Interest paid	$	—		$	—
Income taxes paid	$	—		$	—
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING INFORMATION:
Accounts payable converted into note payable	$	900,000		$	—
Original issue discounts recorded on notes payable	$	—		$	5,400
Debt discounts recorded on convertible notes payable	$	—		$	330,902
Debt/interest converted into common stock and contributed capital	$	70,478		$	308,451

See accompanying notes to financial statements.

F-3

RICH PHARMACEUTICALS, INC.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

SEPTEMBER 30, 2016

NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of Business

On August 9, 2010 the Company was incorporated as Nepia Inc. in the State of Nevada. From August 9, 2010 to July 18, 2013, the Company was in the business of developing, manufacturing, and selling small boilers aimed at farmers primarily in Southeast Asia. Beginning on July 19, 2013, the Company acquired bio-pharmaceutical intellectual property for the treatment of acute myeloid leukemia (AML) and is entering into phase II human studies. The goal is to perfect this indication for marketing purposes for distribution world-wide. On August 26, 2013, as a consequence of our new business direction, the Company changed its name to Rich Pharmaceuticals, Inc. (“Rich” or “the Company”).

On July 18, 2013, the Company designated, from our 10,000,000 authorized shares of preferred stock, par value $0.001, 6,000,000 shares of Series “A” Preferred Stock. Our Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class.

On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 827,670 common shares, and 6,000,000 Series “A” Preferred shares. The common and preferred shares were valued at $123,973. The Company further agreed to use its best efforts to complete a financing resulting in proceeds of at least $2,000,000. If the Company was unable to raise $400,000 according to the terms of the Assignment Agreement, the patent reverts back to Imagic, LLC and its principals. On January 17, 2014, the right of reversion was terminated in exchange for a payment of $20,000.

On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with our boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. In consequence to the Sale Agreement two former officers sold 5,312,925 common shares held by them to our new officer/director. In turn, our new officer/director agreed to cancel 5,002,554 of those shares he received and returned them to treasury for retirement. Certain other shareholders also agreed to cancel 2,625,210 common shares.

On September 5, 2013, the Company increased the authorized common shares, par value $0.0010, from 900,000 shares to 375,030,000 shares. Correspondingly, the Company affirmed a forward split of 4.167 for 1 in which each shareholder was issued 4.167 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split.

Effective February 11, 2016, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 100 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods.

Cash and Cash Equivalents

The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents. At September 30, 2016 and March 31, 2016 the Company had $- and $-, respectively, of unrestricted cash.

F-4

RICH PHARMACEUTICALS, INC.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

SEPTEMBER 30, 2016

NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Basis of Presentation

The financial statements of the Company have been prepared using the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America and are presented in U.S. dollars. The Company has adopted a March 31 fiscal year end.

Certain information and note disclosures normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These condensed financial statements should be read in conjunction with a reading of the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2016, as filed with the U.S. Securities and Exchange Commission.

Property and Equipment

Property and equipment is recorded at cost and is depreciated using the straight-line method over the estimated useful lives of the related assets. The useful lives of the assets are as follows: Computer equipment, 3 years.

Long-Lived and Intangible Assets

The Company accounts for long-lived and intangible assets in accordance with ASC Topic 360-10-05, “Accounting for the Impairment or Disposal of Long-Lived Assets.” ASC Topic 360-10-05 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the historical cost carrying value of an asset may no longer be appropriate. The Company assesses recoverability of the carrying value of an asset by estimating the future net cash flows expected to result from the asset, including eventual disposition. If the future net cash flows are less than the carrying value of the asset, an impairment loss is recorded equal to the difference between the asset’s carrying value and fair value or disposable value. As of March 31, 2014, the Company fully impaired their intangible assets to $0. During the year ended March 31, 2015, the Company acquired another intangible asset from a related party and valued it at the cost of the intangible to the related party totaling $82,120. As of March 31, 2015, the Company fully impaired their intangible assets to $0.

Fair Value of Financial Instruments

The Company’s financial instruments consist of cash and cash equivalents, prepaid expenses, accounts payable, accrued expenses, amounts due to related parties, stock deposits, and a convertible note payable. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements.

Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability. The guidance establishes three levels of inputs that may be used to measure fair value:

F-5

RICH PHARMACEUTICALS, INC.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

SEPTEMBER 30, 2016

NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Fair Value of Financial Instruments (continued)

Level 1 – Observable inputs such as quoted prices in active markets;

Level 2 – Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly;

Level 3 – Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The Company did not have any level 1 or level 3 financial instruments at September 30, 2016 or March 31, 2016. As of September 30, 2016, the derivative liabilities were considered a level 2 item; see Note 8.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Income Taxes

Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.

Revenue Recognition

The Company will recognize revenue when products are fully delivered or services have been provided and collection is reasonably assured.

Research and Development

The Company will charge research and development costs to expense when incurred. The research and development costs include payments made to unrelated third party vendors for their work on enhancements to existing technology, or research into new potentially patentable products or processes.

Stock-Based Compensation

Stock-based compensation is accounted for at fair value in accordance with ASC Topic 718. On September 6, 2013, the Company approved the adoption of Rich Pharmaceuticals, Inc. 2013 Stock Option/Stock Issuance Plan (the "2013 Plan”). The 2013 Plan is intended to aid in recruiting and retaining key employees, directors or consultants and to motivate them by providing incentives through the granting of awards of stock options or other stock based awards. The 2013 Plan is administered by the board of directors. Directors, officers, employees and consultants and our affiliates are eligible to participate under the 2013 Plan. A total of 3,900,048 common shares have been reserved for awards under the 2013 Plan. During the year ended March 31, 2015, the Company granted 197,500 stock options to officers, directors, employees and consultants. During the period ended March 31, 2016, the Company granted 3,900,003 stock options to officers, directors, employees and consultants. The Company made the following modifications to the exercise prices of its options: January 12, 2015, the Company modified the exercise price on all outstanding stock options to $0.17; April 6, 2015, the Company modified the exercise price on all outstanding stock options to $0.08 per share; August 4, 2015, the Company modified the exercise price on all outstanding stock options to $0.01 per share.

F-6

RICH PHARMACEUTICALS, INC.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

SEPTEMBER 30, 2016

NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Basic Loss Per Share

The basic earnings (loss) per share is calculated by dividing the Company’s net income available to common shareholders by the weighted average number of common shares during the year. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity.

Recent Accounting Pronouncements

The Company does not expect the adoption of any other recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

NOTE 2 – PROPERTY AND EQUIPMENT

Property and equipment, recorded at cost, consisted of the following as of September 30, 2016 and March 31, 2016:

	September 30, 2016			March 31, 2016
Computer equipment & furniture	$	5,160		$	5,160
Less: accumulated depreciation		(2,291	)		(1,429	)
Property and equipment, net	$	2,869		$	3,731

The useful life of the computer equipment and furniture is 3 years.

Depreciation expense was $863 and $799 for the periods ended September 30, 2016 and March 31, 2016, respectively.

NOTE 3 – INTANGIBLE ASSETS

On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 827,670 common shares and 6,000,000 Series “A” Preferred Stock. These shares were valued at a total of $123,973. The Company has also paid additional funds to third parties to further the development of this asset and terminate the right of reversion totaling $45,000. The Company analyzed the assets at March 31, 2014 and determined that the value could not be supported and impaired the assets to $0.

On October 6, 2014, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Compositions and methods of use of Phorbol Esters for the treatment of Hodgkin’s Lymphoma”, and all related intellectual property, inventions and trade secrets, data and clinical study results. In consideration for the intellectual property the Company issued 2,207,920 common shares. These shares were valued at a total of $7,904,355; however, since the asset was acquired from a related party the Company valued the asset at the cost of the asset to the related party, $82,120, and treated the excess value as a deemed dividend reducing additional paid in capital. The Company analyzed the assets at March 31, 2015 and determined that the value could not be supported and impaired the assets to $0.

F-7

RICH PHARMACEUTICALS, INC.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

SEPTEMBER 30, 2016

NOTE 4 – ACCRUED EXPENSES

Accrued expenses consisted of the following as of September 30, 2016 and March 31, 2016:

	September 30, 2016		March 31, 2016
Wages and taxes	$	703,756	$	514,713
Accrued interest		57,355		15,437
Total accrued expenses	$	761,111	$	530,150

NOTE 5 – RELATED PARTY DEBT AND TRANSACTIONS

On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with its boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital.

During the year ended March 31, 2015 and 2014, the Company received loans from companies controlled by its new CEO or shareholders totaling $5,000 and $36,000, respectively. The loans are unsecured, non-interest bearing with no specific terms of repayment. The Company repaid all $41,000 of the loans during the year ended March 31, 2015.

Also during the year ended March 31, 2015, the Company received a $6,000 loan from a shareholder. During the period ended September 30, 2016 the Company received an additional $6,280 from this related party. The loan is unsecured and bears 8% interest. There is a total due of $12,280 as of September 30, 2016. Interest accrued on the note as of September 30, 2016 was $597. The Company is in default on the balance of this note.

During the period ending March 31, 2016, the Company received $22,200 in unsecured non-interest bearing loans from related parties and during the period ending September 30, 2016 received an additional $3,100, and has repaid $25,300 of these loans leaving a total due of $- as of September 30, 2016. These loans are deemed to be short-term and are payable at the discretion of the Company.

On September 6, 2013, the Company entered into an Employment Agreement with our Chief Executive Officer, Chief Financial Officer, President and Secretary. The Employment Agreement provides for a term of two years; annual compensation of $275,000, a signing bonus of $68,750, and options to purchase up to 30,002 shares of common stock at an exercise price of $2.00 per share. The CEO earned $137,500 and $275,000 for the periods ended September 30, 2016 and March 31, 2016 (respectively) as a result of this agreement, these amounts contribute to the $531,362 and $395,630 of officer compensation which is included in accrued expenses, as of September 30, 2016 and March 31, 2016.

NOTE 6 – NOTE PAYABLE

On May 31, 2016, the Company issued a secured promissory note in the amount of $900,000. The note is due on August 1, 2017 and bears interest at 10% per annum. The loan replaced an account payable to a legal professional to cover past due amounts and penalties for non-payment. The note is guaranteed personally by two shareholders and collateralized by assets of the company and guarantors. Accrued interest was $30,082 as of September 30, 2016.

F-8

RICH PHARMACEUTICALS, INC.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

SEPTEMBER 30, 2016

NOTE 7 – CONVERTIBLE NOTE PAYABLE

On August 13, 2014, the Company issued a convertible note payable in the amount of $61,111 including an original issue discount of $5,500. The note has a one-time 12% interest charge and is due on August 14, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $61,111 of principal and $6,266 of interest into 1,403,700 shares of common stock leaving a remaining balance of $0. During the year ended March 31, 2016, the note holder converted $1,067 of interest into 177,836 shares of common stock leaving a remaining balance of accrued interest of $0 as of March 31, 2016.

On September 18, 2014, the Company issued a convertible note payable in the amount of $64,500 including an original issue discount of $5,500. The note bears a one-time 12% interest charge and is due on September 18, 2015. The loan becomes convertible immediately upon the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. However, if the market price during the 20 day trading period (mentioned above) is below $0.03, then the conversion factor will be reduced to 55%. During the year ended March 31, 2015, the note holder converted $10,000 of principal into 181,819 shares of common stock leaving a remaining balance of $54,500. During the period ending March 31, 2016 the note holder converted $54,500 in principal and $8,240 in accrued interest into 1,879,597 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016.

On September 23, 2014, the Company issued a convertible note payable in the amount of $55,000. The note bears 8% interest and is due on June 23, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty-five (25) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $25,200 of the principle into 700,000 common shares leaving a remaining balance of $29,800. During the period ending March 31, 2016 the note holder converted $29,800 in principal and $2,158 in accrued interest into 864,672 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016.

On October 6, 2014, the Company issued a convertible promissory note in the amount of $33,000. The note is due on July 6, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $33,000 in principal and $1,320 in accrued interest into 780,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016.

F-9

RICH PHARMACEUTICALS, INC.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

SEPTEMBER 30, 2016

NOTE 7 – CONVERTIBLE NOTE PAYABLE (CONTINUED)

On November 6, 2014, the Company issued a convertible promissory note in the amount of $55,000. The note is due on May 6, 2015 and bears interest at 12% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 52.5% multiplied by lowest daily market price, for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $55,000 in principal and $3,553 in accrued interest into 2,813,634 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016.

On November 25, 2014, the Company issued a convertible promissory note in the amount of $43,000. The note is due on August 28, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder assessed a default fee of $3,510 to increase the balance of the note and also converted $46,510 in principal into 5,290,270 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016.

On December 16, 2014, the Company issued a convertible note payable in the amount of $33,333 including an original issue discount of $3,333. The note bears a one-time 12% interest charge and is due on December 16, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $33,333 in principal and $4000 in accrued interest into 5,047,167 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016.

On January 9, 2015, the Company issued a convertible promissory note in the amount of $33,000. The note is due on October 13, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder assessed a default fee of $16,500 to increase the balance of the note and also converted $49,500 in principal and $1,320 in interest into 8,470,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016.

F-10

RICH PHARMACEUTICALS, INC.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

SEPTEMBER 30, 2016

NOTE 7 – CONVERTIBLE NOTE PAYABLE (CONTINUED)

On February 5, 2015, the Company issued a convertible promissory note in the amount of $54,000. The note is due on November 9, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $33,020 in principal into 12,393,030 shares of common stock, and incurred a default fee of $27,000 leaving a remaining balance of $47,980. Interest accrued on this note as of September 30, 2016 is $5,579. The Company is in default on the balance of this note.

On February 17, 2015, the Company issued a convertible note payable in the amount of $66,780 including an original issue discount of $6,780. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $66,780 in principal and $3,148 in accrued interest into 8,854,031 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016.

On February 25, 2015, the Company issued a convertible note payable in the amount of $27,778 including an original issue discount of $2,778. The note bears a one-time 12% interest charge and is due on February 25, 2017. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $27,778 in principal and $3,333 in accrued interest into 5,185,210 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016.

On March 9, 2015, the Company issued a convertible note payable in the amount of $55,000. The note bears 8% interest and was originally due on December 9, 2015, with a revised due date of June 23, 2017. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty-five (25) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $38,785 in principal and $5,135 in accrued interest into 57,733,852 shares of common stock. During the period ending June 30, 2016 the note holder converted $7,377 in principal and $422 in accrued interest into 46,484,586 shares of common stock leaving a remaining balance of $ 8,838. Accrued interest was $178 as of September 30, 2016.

On March 26, 2015, the Company issued a convertible note payable in the amount of $29,680 including an original issue discount of $1,680. The note bears 8% interest and is due on March 23, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) days prior to the conversion date. During the period ending March 31, 2016 the note holder converted $10,929 in principal into 15,924,728 shares of common stock leaving a remaining balance of $18,751. Accrued interest was $4,520 as of September 30, 2016. The Company is in default on the balance of this note.

F-11

RICH PHARMACEUTICALS, INC.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

SEPTEMBER 30, 2016

NOTE 7 – CONVERTIBLE NOTE PAYABLE (CONTINUED)

On March 2, 2015, the Company issued a convertible note payable in the amount of $58,300 including an original issue discount of $3,300. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible immediately at the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twenty-two (22) trading day period ending on the latest complete trading day prior to the conversion date. On March 2, 2015 the note holder converted $56,402 of the principle into 1,215,551 common shares leaving a remaining balance of $1,898. During the period ending March 31, 2016 the note holder converted $1,898 in principal and $20 in accrued interest into 53,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016.

On May 5, 2015, the Company issued a convertible note payable in the amount of $68,900 including an original issue discount of $3,900. The note bears 8% interest and is due on May 5, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 42% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. . During the period ending March 31, 2016 the note holder converted $8,461 in principal and $566 in accrued interest into 18,135,267 shares of common stock. During the period ending September 30, 2016 the note holder converted $25,939 in principal and $2,675 in accrued interest into 224,358,188 shares of common stock leaving a remaining balance of $34,500. Accrued interest was $3,951 as of September 30, 2016.

On May 6, 2015, the Company issued a convertible note payable in the amount of $10,500. The note bears 8% interest and is due on February 8, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the thirty (30) trading day period ending on the latest complete trading day prior to the conversion date. The Company incurred a default fee of $5,250, leaving a balance of $15,750 as of September 30, 2016. Interest accrued on this note as of September 30, 2016 is $1,451. The Company is in default on the balance of this note.

On May 27, 2015, the Company issued a convertible note payable in the amount of $16,500. The note bears 8% interest rate and is due on May 28, 2016. The loan becomes convertible on May 27, 2015, the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $16,500 in principal and $344 in accrued interest into 2,591,323 shares of common stock leaving a remaining balance of $0. Interest accrued as of March 31, 2016 is $0.

On August 28, 2015, the Company issued a convertible note payable in the amount of $15,000. The note bears 8% interest and is due on August 28, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending September 30, 2016 the note holder converted $15,000 in principal and $939 in accrued interest into 87,032,383 shares of common stock leaving a remaining balance of $0.

F-12

RICH PHARMACEUTICALS, INC.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

SEPTEMBER 30, 2016

NOTE 7 – CONVERTIBLE NOTE PAYABLE (CONTINUED)

On September 4, 2015, the Company issued a convertible note payable in the amount of $19,000. The note bears 8% interest and is due on June 4, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the fifteen (15) trading day period ending on the latest complete trading day prior to the conversion date. The loan balance as of September 30, 2016 is $19,000, and interest accrued as of September 30, 2016 is $1,632.

On December 29, 2015, the Company issued a convertible note payable in the amount of $57,378. The note bears 8% interest rate and was originally due on December 30, 2016, with a revised due date of June 23, 2017. The loan becomes convertible on December 29, 2015, the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $59,934 in principal and $1,222 in accrued interest into 35,927,887 shares of common stock, and incurred a default penalty of $4,165, leaving a remaining balance of $1,609. Interest accrued as of September 30, 2016 is $51.

On January 22, 2016, the Company issued a convertible note payable in the amount of $60,500. The note bears 10% interest and is due on October 22, 2016. The loan becomes convertible on January 22, 2016. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. Interest accrued as of September 30, 2016 is $4,177.

On February 25, 2016, the Company issued a convertible note payable in the amount of $27,500. The note bears 8% interest rate and is due on February 25, 2017. The loan becomes convertible on February 25, 2016, the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date..During the period ending September 30, 2016 the note holder converted $16,745 in principal and $1,380 in interest into 66,500,000 shares of common stock leaving a remaining balance of $10,755. Interest accrued as of September 30, 2016 is $217. This loan has an unamortized original issue discount of $836 as of the end of the period.

On March 24, 2016, the Company issued a convertible note payable in the amount of $7,500. The note bears 8% interest rate and is due on March 24, 2017. The loan becomes convertible on March 24, 2016, the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. Interest accrued as of September 30, 2016 is $312.

F-13

RICH PHARMACEUTICALS, INC.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

SEPTEMBER 30, 2016

NOTE 7 – CONVERTIBLE NOTE PAYABLE (CONTINUED)

On May 25, 2016, the Company issued a convertible note payable in the amount of $30,000. The note bears 8% interest and is due on May 25, 2017. The loan becomes convertible 180 days after issuance or November 21, 2016. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. Interest accrued as of September 30, 2016 is $842.

On June 8, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $84,250. The note bears interest at the rate of 8% and must be repaid on or June 8, 2017. The note and any accrued interest may be converted into shares of Company common stock at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion. Interest accrued as of September 30, 2016 is $2,105.

On June 23, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $56,000. The note bears interest at the rate of 8% and must be repaid on or June 23, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion. Interest accrued as of June 30, 2016 is $1,215.

On July 7, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $58,000. The note bears interest at the rate of 8% and must be repaid on or July 7, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, 180 days after issuance or January 3, 2017, at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion. Interest accrued as of September 30, 2016 is $1,043.

NOTE 8 – DERIVATIVE LIABILITIES

In accordance with AC 815, the Company has bifurcated the conversion feature of their convertible notes and recorded a derivative liability on the date each note became convertible. The derivative liability was then revalued on each reporting date.

As detailed in Note 7 (above) the Company has issued several convertible notes in varying amounts and terms, with the following loans becoming convertible during the periods ending September 30, 2016 and March 31, 2016: $33,000 noted dated October 6, 2014; $55,000 note dated November 6, 2014; $43,000 note dated November 25, 2014; $33,000 note dated January 9, 2015; $54,000 note dated February 5, 2015; $66,780 note dated February 17, 2015;$58,300 note dated March 2, 2015; $55,000 note dated March 9, 2015; $29,680 note dated March 26, 2015; $68,900 note dated May 5, 2015; $10,500 note dated May 6, 2015; $16,500 note dated May 27, 2015; $15,000 note dated August 28, 2015; $19,000 note dated September 4, 2015; $55,000 note dated December 29, 2015; $60,500 note dated January 22, 2016; $27,500 note dated February 25, 2016; $7,500 note dated March 24, 2016.

ASC 815 requires Company management to assess the fair market value of certain derivatives at each reporting period and recognize any change in the fair market value as another income or expense item.  The Company’s only asset or liability measured at fair value on a recurring basis is its derivative liability associated with the above convertible debt.  During the period ended September 30, 2016, the Company recorded a total change in the fair market value of the derivative liabilities of $168,454.

F-14

RICH PHARMACEUTICALS, INC.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

SEPTEMBER 30, 2016

NOTE 8 – DERIVATIVE LIABILITIES (CONTINUED)

The Company uses the Black-Scholes option pricing model to value the derivative liability upon the initial conversion date and at each reporting period.  Included in the model to value the derivative liabilities of the above loans are the following assumptions: stock price at valuation date of $0.0002, exercise price of $0.0001 - $0.000116, dividend yield of zero, years to maturity of 0.060270 – .728770, a risk free rate of 0.29% - 0.59%, and annualized volatility of 284% - 379%. The above loans were all discounted in full with the exception of the March 2, 2015 loan which had a debt discount of $46,370, the May 5, 2015 loan which had an initial debt discount of $41,222, and the May 27, 2015 loan which had an initial debt discount of $15,000. Based on the valuations on the initial valuation dates for the period ending September 30, 2016, the Company recognized debt discounts related to the conversion features totaling $- and a derivative expense of $- related to the excess value of the derivative liabilities. Once the loans are fully converted, the remaining derivative liability is reclassified to equity as additional paid-in capital. As of September 30, 2016, unamortized debt discount, including original issue discounts totaled $16,005. The derivative liabilities totaled $270,531 as of September 30, 2016, of which $- related to long-term debt.

NOTE 9 – EQUITY TRANSACTIONS

The Company has 4,000,000,000 common shares authorized with a par value of $ 0.001 per share.

The Company has 10,000,000 preferred shares authorized with a par value of $ 0.001 per share.

On July 18, 2013, the Company designated, from the 10,000,000 authorized shares of preferred stock, 6,000,000 shares of Series “A” Preferred Stock. The Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class.

On July 18, 2013, the Company granted 6,000,000 Series “A” Preferred shares and 827,670 common shares for the intellectual property. The common and preferred shares were valued at a total of $123,973.

On July 19, 2013, our new officer/director agreed to cancel 5,002,554 common shares and returned them to treasury. Certain other shareholders also agreed to cancel 2,625,210 common shares.

On September 5, 2013, the Company increased the authorized common shares from 900,000 to 375,030,000. Correspondingly, the Company affirmed a forward split of 4.167 for 1 in which each shareholder was issued 4.167 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split.

On October 29, 2013, the Company granted 2,500 units at $30.00 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $50.00 and a one year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below.

On December 11, 2013, the Company granted 2,500 units at $30.00 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $50.00 and a one year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below.

F-15

RICH PHARMACEUTICALS, INC.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

SEPTEMBER 30, 2016

NOTE 9 – EQUITY TRANSACTIONS (CONTINUED)

On June 9, 2015, the Company issued 900,000 units at $0.02 per unit. Each unit consisted of one common stock warrant with an exercise price of $0.02 and a five year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below

On December 15, 2015, the Company issued 4,000,000 units at $0.01 per unit. Each unit consisted of one common stock warrant with an exercise price of $0.01 and a five year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below.

The following is a summary of the inputs used to determine the value of the warrants issued in connection with common stock using the Black-Scholes option pricing model.

Date	June 9, 2015	Dec 15,2015
Warrants	900,000	4,000,000
Stock price on grant date	$0.02	$0.01
Exercise price	$0.02	$0.01
Expected life	5 year	5 year
Volatility	98%	98%
Risk-free rate	1.74%	1.71%
Calculated value	$13,259	$29,612
Fair value allocation of proceeds	$13,259	$29,612

The following is a summary of the warrant activity for the period March 31, 2016 to September 30, 2016:

	Number of warrants		Weighted average exercise price
Outstanding, March 31, 2016		4,930,666	$	0.192
Granted			$	—
Exercised		—		—
Outstanding, September 30, 2016		4,930,666	$	0.192

On April 22, 2015, the Company sold 100,381 shares of common stock for $5,405 in cash, which was paid directly to a vendor for accounts payable.

On June 25, 2015, the Company sold 1,542,455 shares of common stock for $10,797 in cash, of which $3,750 was paid directly to professionals in connection with the expenses of that sale, and $7,047 was retained by the Company.

On July 7, 2015, the Company sold 1,619,423 shares of common stock for $11,336 in cash, of which $3,750 was paid directly to a vendor for professional services.

On July 15, 2015, the Company sold 1,439,282 shares of common stock for $10,075 in cash.

On October 27, 2015, the Company sold 1,648,840 shares of common stock for $11,542 in cash.

During the periods ended September 30, 2016 and March 31, 2016, the Company received, as listed, conversion notices from various note holders. The Company issued the following common shares to satisfy the conversion of the following debt and interest:

On February 8, 2016, the Company approved a change in the authorized shares of common stock to 4,000,000,000 shares.

F-16

RICH PHARMACEUTICALS, INC.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

SEPTEMBER 30, 2016

NOTE 9 – EQUITY TRANSACTIONS (CONTINUED)

Effective February 11, 2016, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 100 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods.

The Company accounts for employee stock-based compensation in accordance with the guidance of ASC Topic 718: Compensation - Stock Compensation, which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values

The Company follows ASC Topic 505-50, formerly EITF 96-18, “Accounting for Equity Instruments that are Issued to Other than Employees for Acquiring, or in Conjunction with Selling Goods and Services,” for stock options and warrants issued to consultants and other non-employees. In accordance with ASC Topic 505-50, these stock options issued as compensation for services provided to the Company are accounted for based upon the fair value of the services provided or the estimated fair market value of the option, whichever can be more clearly determined.

During the year ended March 31, 2014, the Company granted 475,033 stock options to officers, directors, employees and consultants. During the year ended March 31, 2015, the Company granted 197,500 stock options to officers, directors, employees and consultants. During the period ended March 31, 2016, the Company granted 3,900,003 stock options to officers, directors, employees and consultants The options have been re-priced twice as follows: (1) Effective January 12, 2015, the Company approved the re-pricing of all 672,533 previously granted options under the Company’s 2013 Equity Incentive Plan, which had exercise prices between $1.91984 per share and $30.0 per share, to $0.17 per share which was the closing price of the Company’s common stock on January 9, 2015. All of the other terms of the options remained unchanged.

F-17

RICH PHARMACEUTICALS, INC.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

SEPTEMBER 30, 2016

NOTE 9 – EQUITY TRANSACTIONS (CONTINUED)

Date	Debt/Interest Converted	Common Stock Issued	Price per Share
April 1, 2015	$16,650	411,111	$0.04050
April 6, 2015	$10,000	209,644	$0.04770
April 8, 2015	$15,309	453,561	$0.03375
April 8, 2015	$20,001	454,545	$0.04400
April 9, 2015	$14,320	325,455	$0.04400
April 14, 2015	$10,000	236,967	$0.04220
April 16, 2015	$1,918	53,000	$0.03619
April 21, 2015	$10,000	259,740	$0.03850
April 29, 2015	$15,000	389,610	$0.03850
May 4, 2015	$5,083	131,464	$0.03866
May 12, 2015	$28,456	903,380	$0.03150
May 20, 2015	$20,199	947,645	$0.02131
May 20, 015	$17,240	783,636	$0.02200
May 27, 2015	$13,568	701,801	$0.01933
May 29, 2015	$15,000	882,353	$0.01700
June 11, 2015	$9,897	942,609	$0.01050
June 16, 2015	$14,100	1,175,000	$0.01200
June 16, 2015	$13,565	1,130,417	$0.01200
June 22, 2015	$7,415	1,235,833	$0.00600
June 22, 2015	$14,384	2,479,924	$0.00580
June 23, 2015	$7,752	1,292,000	$0.00600
September 16, 2015	$7,974	1,772,033	$0.00450
September 28, 2015	$10,000	1,666,667	$0.00600
September 29, 2015	$10,620	1,770,000	$0.00600
October 7, 2015	$2,250	375,000	$0.00600
October 7, 2015	$8,400	1,400,000	$0.00600
October 19, 2015	$9,720	1,620,000	$0.00600
November 2, 2015	$4,424	1,966,124	$0.00225
November 23, 2015	$10,000	1,666,667	$0.00600
November 30, 2015	$16,844	2,591,323	$0.00650
December 9, 2015	$1,746	775,991	$0.00225
December 17, 2015	$5,332	919,319	$0.00580
December 28, 2015	$1,341	596,200	$0.00225
December 28, 2015	$17,700	2,950,000	$0.00600
December 28, 2015	$14,305	2,384,167	$0.00600
December 28, 2015	$14,963	2,579,916	$0.00580
December 29, 2015	$8,395	1,399,167	$0.00600
December 29, 2015	$7,670	1,278,333	$0.00600
December 30, 2015	$6,651	2,956,248	$0.00225
January 1, 2016	$28,500	4,384,615	$0.00650
January 4, 2016	$19,339	3,223,213	$0.00600
January 5, 2016	$8,107	3,603,227	$0.00225
January 6, 2016	$16,070	2,678,333	$0.00600
January 6, 2016	$16,597	2,861,607	$0.00580
February 16 ,2016	$1,424	4,220,400	$0.00034
February 17, 2016	$12,800	8,443,272	$0.00152
February 23, 2016	$4,640	4,218,182	$0.00110
February 23, 2016	$3,086	4,200,871	$0.00073
February 24, 2016	$1,492	4,419,970	$0.00034
February 25, 2016	$3,000	2,638,987	$0.00114
February 25, 2016	$4,640	4,218,182	$0.00110
March 1, 2016	$1,313	5,834,458	$0.00022
March 2, 2016	$4,600	5,831,643	$0.00079
March 2, 2016	$1,650	2,586,410	$0.00064
March 2, 2016	$9,332	11,650,000	$0.00080
March 7, 2016	$2,799	6,546,292	$0.00043
March 11, 2016	$1,924	4,147,500	$0.00046
March 14, 2016	$2,245	7,125,777	$0.00032
March 15, 2016	$3,329	7,454,098	$0.00045
March 15, 2016	$5,210	11,450,000	$0.00046
March 22, 2016	$2,419	8,957,888	$0.00027
March 22, 2016	$2,367	7,200,486	$0.00033
March 22, 2016	$5,315	11,682,000	$0.00046
March 28, 2016	$1,986	8,958,779	$0.00022
March 31, 2016 Total	$602,376	194,603,040

F-18

RICH PHARMACEUTICALS, INC.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

SEPTEMBER 30, 2016

NOTE 9 – EQUITY TRANSACTIONS (CONTINUED)

Date	Debt/Interest Converted	Common Stock Issued	Price per Share
April 1, 2016	$2,197	9,766,311	$0.000225
April 4, 2016	$4,847	17,250,000	$0.000281
April 7, 2016	$1,750	9,722,222	$0.000180
April 14, 2016	$4,158	19,250,000	$0.000216
April 15, 2016	$1,318	9,766,222	$0.000135
April 26, 2016	$1,705	12,629,776	$0.000135
May 4, 2016	$2,067	9,718,025	$0.000213
May 31, 2016	$   828	4,600,055	$0.000180
June 2, 2016	$9,120	30,000,000	$0.000304
June 2, 2016	$4,401	29,340,333	$0.000150
June 14, 2016	$5,847	29,235,900	$.0.000200
June 17,2016	$5,691	28,456,150	$0.000200
June 29, 2016	$6,580	21,270,355	$0.000309
August 23, 2016	$2,567	22,129,741	$0.000116
August 29, 2016	$2,570	22,156,120	$0.000116
September 6, 2016	$2,547	21,952,672	$0.000116
September 20, 2016	$2,443	25,267,655	$0.000097
September 26, 2016	$2,946	25,393,448	$0.000116
September 28, 2016	$2,947	25,403,448	$0.000116
September 30, 2016	$3,949	51,066,724	$0.000077
September 30, 2016 Total	$70,478	424,375,157

(2) Effective April 6, 2015, the Company approved the re-pricing of all 2,712,535 previously granted options under the Company’s 2013 Equity Incentive Plan, which had exercise prices between $.08 per share and $0.17 per share, to $0.08 per share which was the closing price of the Company’s common stock on April 6, 2015. All of the other terms of the options remained unchanged. (3) Effective August 4, 2015, the Company approved the re-pricing of all 3,712,535 previously granted options under the Company’s 2013 Equity Incentive Plan, which had exercise prices between $.08 per share and $0.02 per share, to $0.02 per share which was the closing price of the Company’s common stock on August 4, 2015. All of the other terms of the options remained unchanged. The Company revalued all existing options on January 12, 2015 and again on April 6, 2015, and again on August 4, 2015 using the Black-Scholes option pricing model using the initial terms of the options and the modified terms of the options. The difference in the valuations was recorded as additional expense. The re-pricing of the options resulted in the recognition of an additional $50,448 on January 9, 2015 and an additional $9,316 on April 6, 2015, and an additional $47,463 on August 4, 2015 in related stock based compensation expense for those periods.

The following is a summary of the inputs used to determine the value of the options using the Black-Scholes option pricing model.

Date	April 6, 2015	June 9, 2015	December 15, 2015
Options	2,040,003	1,000,000	860,000
Stock price grant date	$0.08	$0.02	$0.01
Initial Exercise price	$0.08	$0.02	$0.01
Modified Exercise price	$0.01	$0.01	$0.01
Expected life	5.0	5.0	5.0
Volatility	99%	99%	84%
Risk-free rate	1.31%	1.74%	1.70%
Calculated value	$120,778	$14,838	$5,736
Modified value	$151,221	$16,347	$5,736

F-19

RICH PHARMACEUTICALS, INC.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

SEPTEMBER 30, 2016

NOTE 9 – EQUITY TRANSACTIONS (CONTINUED)

The following is a summary of the option activity for the period March 31, 2015 through September 30, 2016:

	Number of options	Weighted average exercise price
Outstanding, March 31, 2015	672,533	$0.01
Granted	3,900,003	$0.01
Exercised	-	-
Expired	-	-
Outstanding, September 30, 2016	4,572,536	$0.01

NOTE 10 – COMMITMENTS AND CONTINGENCIES

The Company leases office space on a verbal month-to-month agreement. Monthly rent is approximately $2,800.

On July 8, 2016, the Company engaged a foreign based company to evaluate the safety and efficacy of RP-323 over a 27 month period. The contract stipulates a commitment of $193,255 with additional fees for pass-through expenses.

The inventor of the intellectual property which was assigned to Rich Pharmaceuticals, Inc. in July 2013 by Imagic, LLC and Richard L. Chang’s Holdings, LLC is presently in declaratory relief litigation with Biosuccess Biotech, Co. LTD. (“Biosuccess”), a company who was previously assigned licensing rights in the intellectual property. In connection with this litigation, on January 17, 2014, the Company received notice of a complaint filed by Biosuccess against the Company, Imagic, LLC, Richard L. Chang’s Holdings, LLC, and Ben Chang (our CEO and a director) in the United States District Court, Central District of California Western Division (the “District Court”). The Complaint includes allegations of patent and copyright infringement, misappropriation of trade secrets, breach of fiduciary duty, unfair competition and other causes of actions against the Company, Imagic, LLC, Richard L. Chang’s Holdings, LLC, and Ben Chang (the “Litigation”). The Complaint seeks relief which includes compensatory damages, attorneys’ fees and costs, an award of treble damages, and such other relief as the court may deem just and proper. As previously disclosed on January 4, 2016, the Litigation has been settled through a confidential mediation process supervised by the Federal Court and the Litigation has been dismissed with prejudice by the Federal Court. The Company incurred substantial fees in defending the litigation.

NOTE 11 – LIQUIDITY AND GOING CONCERN

The Company has a working capital deficit, has not yet received revenues from sales of products or services, and has incurred losses since inception. These factors create substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern.

The ability of the Company to continue as a going concern is dependent on the Company generating cash from the sale of its common stock and/or obtaining debt financing and attaining future profitable operations. Management’s plans include selling its equity securities and obtaining debt financing to fund its capital requirement and ongoing operations; however, there can be no assurance the Company will be successful in these efforts.

F-20

RICH PHARMACEUTICALS, INC.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

SEPTEMBER 30, 2016

NOTE 12 – SUBSEQUENT EVENTS

On October 7, 2016, the Company converted $3,035 in principle and $346 in interest on a convertible note payable into 58,291,551 shares of common stock.

On October 14, 2016, the Company converted $3,030 in principle and $350 in interest on a convertible note payable into 58,275,689 shares of common stock.

On October 21, 2016, the Company converted $3,033 in principle and $355 in interest on a convertible note payable into 58,355,689 shares of common stock.

On October 26, 2016, the Company converted $3,025 in principle and $358 in interest on a convertible note payable into 58,316,551 shares of common stock.

On October 20, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $58,000. The note bears interest at the rate of 8% and must be repaid on or October 20, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, 180 days after issuance or January 3, 2017, at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion.

On October 28, 2016, the Company issued an 8% convertible redeemable promissory note in the principal amount of $32,000. The note must be repaid on or before October 20, 2017. The note and any accrued interest may be converted by the lender into shares of Company common stock 180 days after issuance or April 26, 2017, at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion.

On November 7, 2016, the Company converted $5,015 of debt and interest on a convertible note payable into 86,472,931 shares of common stock.

In accordance with ASC 855-10, the Company has analyzed its operations subsequent to September 30, 2016 to the date these financial statements were issued, and has determined that it does not have any material subsequent events to disclose in these financial statements other than the events described above.

F-21

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations Company Overview

Results of Operations for the Three and Six Months Ended September 30, 2016

We generated no revenue for the three and six months ended September 30, 2016. We do not anticipate earnings revenues until we are able to sell or license our products.

Our operating expenses and net loss during the three and six months ended September 30, 2016 were $182,795 and $398,272 respectively, as compared with $234,528 and $560,442 for the same period ended 2015. The operating expenses for the three months ended September 30, 2016 consisted mainly of professional fees ($34,158), wages and taxes ($96,001), and office expense ($35,472). The operating expenses for the six months ended September 30, 2016 consisted mainly of professional fees ($88,401), wages and taxes ($191,956), and office expense ($70,046).

The operating expenses for the three months ended September 30, 2015 consisted mainly of professional fees ($26,338), wages and taxes ($91,071), office expense ($25,140) and stock based compensation ($62,301). The operating expenses for the six months ended September 30, 2015 consisted mainly of professional fees ($92,285), wages and taxes ($182,793), office expense ($45,894) and stock based compensation of ($192,392).

We anticipate our operating expenses will continue to increase with our plan of operations.

Liquidity and Capital Resources

As of September 30, 2016, we had total current assets of $0; we had total current liabilities of $2,761,048; and we had a stockholders’ deficit of $2,758,179. Operating activities used $190,438 in cash for the six months ended September 30, 2016.

Our net loss of $444,883 for the six months ended September 30, 2016 primarily accounted for our negative operating cash flow. Financing activities during the six months ended September 30, 2016 generated $190,438 in cash.

As of September 30, 2016 and the date of this report, we have insufficient cash to operate our business at the current level for the next twelve months and insufficient cash to achieve our business goals. Our continuation as a going concern is dependent upon our ability to obtain additional financing and to generate profits and positive cash flow. We will require additional cash of $2,000,000 over the next twelve months to cover the costs of overhead and operations, drug manufacturing, maintaining our patent portfolio, and conducting clinical trials for the indication Acute Myeloid Leukemia (“AML”). We intend to raise the required capital pursuant to private debt or equity financings in the near term, but there is no guarantee or assurances that we will be able to do so. 

Off Balance Sheet Arrangements

As of September 30, 2016, there were no off balance sheet arrangements.

Going Concern

We have negative working capital and have not yet received revenues from sales of products or services. These factors create substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustment that might be necessary if we are unable to continue as a going concern.

Our ability to continue as a going concern is dependent on generating cash from the sale of our common stock and/or obtaining debt financing and attaining future profitable operations. Management’s plans include selling our equity securities and obtaining debt financing to fund our capital requirement and ongoing operations; however, there can be no assurance we will be successful in these efforts.

4

Item 3. Quantitative and Qualitative Disclosures About Market Risk

A smaller reporting company is not required to provide the information required by this Item.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

We carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of September 30, 2016. This evaluation was carried out under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of September 30, 2016, our disclosure controls and procedures were not effective due to the presence of material weaknesses in internal control over financial reporting.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis. Management has identified the following material weaknesses which have caused management to conclude that, as of September 30, 2016, our disclosure controls and procedures were not effective: (i) inadequate segregation of duties and effective risk assessment; and (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC guidelines.

Remediation Plan to Address the Material Weaknesses in Internal Control over Financial Reporting

We plan to take steps to enhance and improve the design of our internal controls over financial reporting. During the period covered by this quarterly report on Form 10-Q, we were not been able to remediate the material weaknesses identified above. To remediate such weaknesses, and subject to our ability to obtain additional funding, we plan to implement the following changes during our fiscal year ending March 31, 2016: (i) appoint additional qualified personnel to address inadequate segregation of duties and ineffective risk management; and (ii) adopt sufficient written policies and procedures for accounting and financial reporting. The remediation efforts set out are largely dependent upon our securing additional financing to cover the costs of implementing the changes required. If we are unsuccessful in securing such funds, remediation efforts may be adversely affected in a material manner.

Changes in Internal Control over Financial Reporting

There were no changes in the Company’s internal controls over financial reporting during the period ended September 30, 2016 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

5

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

The inventor of the intellectual property which was assigned to the Company in July 2013 by Imagic, LLC and Richard L. Chang’s Holdings, LLC is presently in declaratory relief litigation with Biosuccess Biotech, Co. LTD. (“Biosuccess”), a company who was previously assigned licensing rights in the intellectual property. In connection with this litigation, on January 17, 2014, the Company received notice of a complaint filed by Biosuccess against the Company, Imagic, LLC, Richard L. Chang’s Holdings, LLC, and Ben Chang (our CEO and a director) in the United States District Court, Central District of California Western Division (the “District Court”). The Complaint includes allegations of patent and copyright infringement, misappropriation of trade secrets, breach of fiduciary duty, unfair competition and other causes of actions against the Company, Imagic, LLC, Richard L. Chang’s Holdings, LLC, and Ben Chang (the “Litigation”). The Complaint seeks relief which includes compensatory damages, attorneys’ fees and costs, an award of treble damages, and such other relief as the court may deem just and proper. As previously disclosed on January 4, 2016, the Litigation has been settled through a confidential mediation process supervised by the Federal Court and the Litigation has been dismissed with prejudice by the Federal Court. The Company incurred substantial legal fees in defending the Litigation. 

Item 1A: Risk Factors. An investment in our common stock involves a high degree of risk. You should carefully consider the risks described below, together with all of the other information included in this quarterly report on Form 10Q, before making an investment decision. If any of the following risks actually occurs, our business, financial condition or results of operations could suffer. In that case, the trading price of our common stock could decline, and you may lose all or part of your investment. You should read the above section entitled "Forward-Looking Statements" for a discussion of what types of statements are forward-looking statements as well as the significance of such statements in the context of this report.

Risks Related To Our Business

We are a development stage company and may never commercialize any of our products or services or earn a profit. Prior to July 19, 2013, we were a “shell” company with no or nominal operations. We recently became funded and commenced operations. We are a development stage company in the business of developing treatments for Acute Myelogenous Leukemia (AML). We currently have no products ready for commercialization, have not generated any revenue from operations and expect to incur substantial net losses for the foreseeable future to further develop and commercialize our technology. We cannot predict the extent of these future net losses, or when we may attain profitability, if at all. If we are unable to generate significant revenue from our technology or attain profitability, we will not be able to sustain operations. Because of the numerous risks and uncertainties associated with developing and commercializing our technology, we are unable to predict the extent of any future losses or when we will become profitable, if ever. We may never become profitable and you may never receive a return on an investment in our common stock. An investor in our common stock must carefully consider the substantial challenges, risks and uncertainties inherent in the attempted development and commercialization of medical treatments. We may never successfully commercialize our technology, and our business may fail.

We will need to raise substantial additional capital to commercialize our technology, and our failure to obtain funding when needed may force us to delay, reduce or eliminate our product development programs or collaboration efforts. As of the date of this Annual Report on Form 10K, we have limited cash resources. Due to our expectation that we will continue to incur losses in the future, we will be required to raise additional capital to complete the development and commercialization of our technology. During the next 12 months and potentially thereafter, we will have to raise additional funds to continue the development and commercialization of our technology. When we seek additional capital, we may seek to sell additional equity and/or debt securities or to obtain a credit facility, which we may not be able to do on favorable terms, or at all. Our ability to obtain additional financing will be subject to a number of factors, including market conditions, our operating performance and investor sentiment. If we are unable to raise additional capital when required or on acceptable terms, we may have to significantly delay, scale back or discontinue the development and/or commercialization of one or more of our technologies, restrict our operations or obtain funds by entering into agreements on unattractive terms.

Our ability to successfully commercialize our technology will depend largely upon the extent to which third-party payors reimburse the costs for our treatment in the future. Physicians and patients may decide not to order our products unless third-party payors, such as managed care organizations as well as government payors such as Medicare and Medicaid pay a substantial portion of the price of the treatment. Reimbursement by a third-party payor may depend on a number of factors, including a payor’s determination that our product candidates are:

• not experimental or investigational;

• effective;

• medically necessary;

• appropriate for the specific patient;

• cost-effective;

• supported by peer-reviewed publications; and

• included in clinical practice guidelines.

6

Market acceptance, sales of products based upon our technology, and our profitability may depend on reimbursement policies and health care reform measures. Several entities conduct technology assessments of medical treatments and provide the results of their assessments for informational purposes to other parties. These assessments may be used by third-party payors and health care providers as grounds to deny coverage for a treatment or procedure. The levels at which government authorities and third-party payors, such as private health insurers and health maintenance organizations, may reimburse the price patients pay for such products could affect whether we are able to commercialize our products. Our technology may receive negative assessments that may impact our ability to receive reimbursement of the treatment. Since each payor makes its own decision as to whether to establish a policy to reimburse a treatment, seeking these approvals may be a time-consuming and costly process. We cannot be sure that reimbursement in the U.S. or elsewhere will be available for any of our products in the future. If reimbursement is not available or is limited, we may not be able to commercialize our products.

If we are unable to obtain reimbursement approval from private payors and Medicare and Medicaid programs for our product candidates, or if the amount reimbursed is inadequate, our ability to generate revenues could be limited. Even if we are being reimbursed, insurers may withdraw their coverage policies or cancel their contracts with us at any time, stop paying for our treatment or reduce the payment rate for our treatment, which would reduce our revenue.

The commercial success of our product candidates will depend upon the degree of market acceptance of these products among physicians, patients, health care payors and the medical community. The use of our treatment technology has never been commercialized for any indication. Even if approved for sale by the appropriate regulatory authorities, physicians may not order treatment based upon out technology, in which event we may be unable to generate significant revenue or become profitable. Acceptance of our technology will depend on a number of factors including:

• acceptance of products based upon our technology by physicians and patients;

• successful integration into clinical practice;

• adequate reimbursement by third parties;

• cost effectiveness;

• potential advantages over alternative treatments; and

• relative convenience and ease of administration.

We will need to make leading physicians aware of the benefits of using our technology through published papers, presentations at scientific conferences and favorable results from our clinical studies. In addition, we will need to gain support from thought leaders who believe that our treatment will provide superior results. Ideally, we will need these individuals to publish support papers and articles which will be necessary to gain acceptance of our products. There is no guarantee that we will be able to obtain this support. Our failure to be successful in these efforts would make it difficult for us to convince medical practitioners to order our treatment for their patients and consequently our revenue and profitability will be limited.

If our potential treatments are unable to compete effectively with current and future treatments targeting similar markets as our potential products, our commercial opportunities will be reduced or eliminated. The medical treatment industry for AML and stroke is intensely competitive and characterized by rapid technological progress. In each of our potential product areas, we face significant competition from large biotechnology, medical diagnostic and other companies. The technologies associated with the medical industry are evolving rapidly and there is intense competition within such industry. Certain companies have established technologies that may be competitive to our technology and any future products that we develop. Some of these competing companies may use different approaches or means to obtain results, which could be more effective or less expensive than our treatments. Moreover, these and other future competitors have or may have considerably greater resources than we do in terms of technology, sales, marketing, commercialization and capital resources. These competitors may have substantial advantages over us in terms of research and development expertise, experience in clinical studies, experience in regulatory issues, brand name exposure and expertise in sales and marketing as well as in operating central laboratory services. Many of these organizations have financial, marketing and human resources greater than ours; therefore, there can be no assurance that we can successfully compete with present or potential competitors or that such competition will not have a materially adverse effect on our business, financial position or results of operations.

Since our technology is under development, we cannot predict the relative competitive position of any product based upon the technology. However, we expect that the following factors will determine our ability to compete effectively: safety and efficacy; product price; turnaround time; ease of administration; performance; reimbursement; and marketing and sales capability.

If our clinical studies do not prove the superiority of our technologies, we may never sell our products and services. The results of our clinical studies may not show that treatment results using our technology are superior to existing treatment. In that event, we will have to devote significant financial and other resources to further research and development, and commercialization of products using our technologies will be delayed or may never occur.

7

If we do not receive regulatory approvals, we may not be able to develop and commercialize our technology. We will need FDA approval to market products based on our technology in the United States and approvals from foreign regulatory authorities to market products based on our technology outside the United States. We have not yet filed an application with the FDA to obtain approval to market any of our proposed products. If we fail to obtain regulatory approval for the marketing of products based on our technology, we will be unable to sell such products and will not be able to sustain operations. The regulatory review and approval process, which may include evaluation of preclinical studies and clinical trials of products based on our technology, as well as the evaluation of manufacturing processes and contract manufacturers’ facilities, is lengthy, expensive and uncertain. Securing regulatory approval for products based upon our technology may require the submission of extensive preclinical and clinical data and supporting information to regulatory authorities to establish such products’ safety and effectiveness for each indication. We have limited experience in filing and pursuing applications necessary to gain regulatory approvals.

Regulatory authorities generally have substantial discretion in the approval process and may either refuse to accept an application, or may decide after review of an application that the data submitted is insufficient to allow approval of any product based upon our technology. If regulatory authorities do not accept or approve our applications, they may require that we conduct additional clinical, preclinical or manufacturing studies and submit that data before regulatory authorities will reconsider such application. We may need to expend substantial resources to conduct further studies to obtain data that regulatory authorities believe is sufficient. Depending on the extent of these studies, approval of applications may be delayed by several years, or may require us to expend more resources than we may have available. It is also possible that additional studies may not suffice to make applications approvable. If any of these outcomes occur, we may be forced to abandon our applications for approval, which might cause us to cease operations.

If we are unable to protect our intellectual property effectively, we may be unable to prevent third parties from using our technologies, which would impair our competitive advantage. We will rely on patent protection as well as a combination of copyright and trade secret protection, and other contractual restrictions to protect our proprietary technologies, all of which provide limited protection and may not adequately protect our rights or permit us to gain or keep any competitive advantage. If we fail to protect our intellectual property, we will be unable to prevent third parties from using our technologies and they will be able to compete more effectively against us. We cannot assure you that the patent issued to us will not be challenged, invalidated or held unenforceable. We cannot guarantee you that we will be successful in defending challenges made in connection with our patent and any future patent applications. In addition to our patent and any future patent applications, we will rely on contractual restrictions to protect our proprietary technology. We will require our employees and third parties to sign confidentiality agreements and employees to also sign agreements assigning to us all intellectual property arising from their work for us. Nevertheless, we cannot guarantee that these measures will be effective in protecting our intellectual property rights. 

We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights and we may be unable to protect our rights to, or use, our technology. The inventor of the intellectual property which was assigned to the Company in July 2013 by Imagic, LLC and Richard L. Chang’s Holdings, LLC is presently in declaratory relief litigation with Biosuccess Biotech, Co. LTD. (“Biosuccess”), a company who was previously assigned licensing rights in the intellectual property. In connection with this litigation, on January 17, 2014, the Company received notice of a complaint filed by Biosuccess against the Company, Imagic, LLC, Richard L. Chang’s Holdings, LLC, and Ben Chang (our CEO and a director) in the United States District Court, Central District of California Western Division (the “District Court”). The Complaint includes allegations of patent and copyright infringement, misappropriation of trade secrets, breach of fiduciary duty, unfair competition and other causes of actions against the Company, Imagic, LLC, Richard L. Chang’s Holdings, LLC, and Ben Chang (the “Litigation”). The Complaint seeks relief which includes compensatory damages, attorneys’ fees and costs, an award of treble damages, and such other relief as the court may deem just and proper. As previously disclosed on January 4, 2016, the Litigation has been settled through a confidential mediation process supervised by the Federal Court and the Litigation has been dismissed with prejudice by the Federal Court. The Company incurred substantial legal fees in defending the Litigation.

Also, our competitors may have filed, and may in the future file, patent applications covering technology similar to ours. Any such patent application may have priority over our patent applications and could further require us to obtain rights to issued patents covering such technologies. There may be third-party patents, patent applications and other intellectual property relevant to our potential products that may block or compete with our products or processes. If another party has filed a United States patent application on inventions similar to ours, we may have to participate in an interference proceeding declared by the United States Patent and Trademark Office to determine priority of invention in the United States. The costs of these proceedings could be substantial, and it is possible that such efforts would be unsuccessful, resulting in a loss of our United States patent position with respect to such inventions. In addition, we cannot assure you that we would prevail in any of these suits or that the damages or other remedies if any, awarded against us would not be substantial. Claims of intellectual property infringement may require us to enter into royalty or license agreements with third parties that may not be available on acceptable terms, if at all. We may also become subject to injunctions against the further development and use of our technology, which would have a material adverse effect on our business, financial condition and results of operations. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations.

8

Our financial statements have been prepared assuming that the Company will continue as a going concern. We have generated losses to date and have limited working capital. These factors raise substantial doubt about our ability to continue as a going concern. Our financial statements do not include any adjustments that might result from this uncertainty. The report of our independent registered public accounting firm included an explanatory paragraph expressing substantial doubt about our ability to continue as a going concern in their audit report included herein. If we cannot generate the required revenues and gross margin to achieve profitability or obtain additional capital on acceptable terms, we will need to substantially revise our business plan or cease operations and an investor could suffer the loss of a significant portion or all of his investment in our Company.

We do not expect to pay dividends for the foreseeable future, and we may never pay dividends and, consequently, the only opportunity for investors to achieve a return on their investment is if a trading market develops and investors are able to sell their shares for a profit or if our business is sold at a price that enables investors to recognize a profit.   We currently intend to retain any future earnings to support the development and expansion of our business and do not anticipate paying cash dividends for the foreseeable future. Our payment of any future dividends will be at the discretion of our Board of Directors after taking into account various factors, including but not limited to our financial condition, operating results, cash needs, growth plans and the terms of any credit agreements that we may be a party to at the time. In addition, our ability to pay dividends on our common stock may be limited by state law. Accordingly, we cannot assure investors any return on their investment, other than in connection with a sale of their shares or a sale of our business. At the present time there is a limited trading market for our shares. Therefore, holders of our securities may be unable to sell them. We cannot assure investors that an active trading market will develop or that any third party will offer to purchase our business on acceptable terms and at a price that would enable our investors to recognize a profit.

Corporate and Other Risks

Limitations on director and officer liability and indemnification of our Company’s officers and directors by us may discourage stockholders from bringing suit against an officer or director.  Our Company’s certificate of incorporation and bylaws provide, with certain exceptions as permitted by governing state law, that a director or officer shall not be personally liable to us or our stockholders for breach of fiduciary duty as a director, except for acts or omissions which involve intentional misconduct, fraud or knowing violation of law, or unlawful payments of dividends. These provisions may discourage stockholders from bringing suit against a director for breach of fiduciary duty and may reduce the likelihood of derivative litigation brought by stockholders on our behalf against a director.

We are responsible for the indemnification of our officers and directors. Should our officers and/or directors require us to contribute to their defense, we may be required to spend significant amounts of our capital. Our certificate of incorporation and bylaws also provide for the indemnification of our directors, officers, employees, and agents, under certain circumstances, against attorney's fees and other expenses incurred by them in any litigation to which they become a party arising from their association with or activities on behalf of our Company. This indemnification policy could result in substantial expenditures, which we may be unable to recoup. If these expenditures are significant, or involve issues which result in significant liability for our key personnel, we may be unable to continue operating as a going concern.

Certain provisions of our Certificate of Incorporation may make it more difficult for a third party to effect a change-of-control. Our certificate of incorporation authorizes the Board of Directors to issue up to 10,000,000 shares of preferred stock. The preferred stock may be issued in one or more series, the terms of which may be determined at the time of issuance by the Board of Directors without further action by the stockholders. These terms may include preferences as to dividends and liquidation, conversion rights, redemption rights and sinking fund provisions. The issuance of any preferred stock could diminish the rights of holders of our common stock, and therefore could reduce the value of such common stock. In addition, specific rights granted to future holders of preferred stock could be used to restrict our ability to merge with, or sell assets to, a third party. The ability of the Board of Directors to issue preferred stock could make it more difficult, delay, discourage, prevent or make it more costly to acquire or effect a change-in-control, which in turn could prevent our stockholders from recognizing a gain in the event that a favorable offer is extended and could materially and negatively affect the market price of our common stock.

The issuance of Preferred Stock to our Chief Executive Officer provides him with voting control which may limit your ability and the ability of our other stockholders, whether acting alone or together, to propose or direct the management or overall direction of our Company. Our Chief Executive Officer has 6,000,000 shares of Preferred Stock which provide him with 100 to 1 voting rights over shares of common stock. This ownership provides him with voting control over matters which require shareholder approval. This concentration of voting power could discourage or prevent a potential takeover of our Company that might otherwise result in an investor receiving a premium over the market price for his shares. If you acquire shares of our common stock, you may have no effective voice in the management of our Company.  Such concentrated control of our Company may adversely affect the price of our common stock. Our principal stockholders may be able to control matters requiring approval by our stockholders, including the election of directors, mergers or other business combinations. Such concentrated control may also make it difficult for our stockholders to receive a premium for their shares of our common stock in the event we merge with a third party or enter into different transactions which require stockholder approval. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock. 

We are dependent for our success on a few key individuals.  Our success depends on the skills, experience and performance of key members of our management team.  Each of those individuals may voluntarily terminate his relationship with the Company at any time. Were we to lose one or more of these key individuals, we would be forced to expend significant time and money in the pursuit of a replacement, which would result in both a delay in the implementation of our business plan and the diversion of limited working capital. We do not maintain a key man insurance policy on any of our executive officers.

9

Capital Market Risks

Our common stock recently commenced trading and has limited volume and high price volatility, so you may be unable to sell your shares to raise money or otherwise desire to liquidate your shares.  The Company’s common stock commenced trading March 14, 2014 on the OTC Markets. The trading volume has been very limited by the fact that many major institutional investment funds, including mutual funds, as well as individual investors follow a policy of not investing in OTC stocks and certain major brokerage firms restrict their brokers from recommending OTC stocks because they are considered speculative, volatile, thinly traded and the market price of the common stock may not accurately reflect our underlying value. The market price of our common stock is subject to wide fluctuations, and may be subject to further fluctuations based on announcements of new products or services by us, significant sales of our common stock, including “short” sales, the operating and stock price performance of other companies that investors may deem comparable to us, and news reports relating to trends in our markets or general economic conditions.

The application of the “penny stock” rules to our common stock could limit the trading and liquidity of the common stock, adversely affect the market price of our common stock and increase your transaction costs to sell those shares. As long as the trading price of our common stock is below $5 per share, the open-market trading of our common stock will be subject to the “penny stock” rules, unless we otherwise qualify for an exemption from the “penny stock” definition. The “penny stock” rules impose additional sales practice requirements on certain broker-dealers who sell securities to persons other than established customers and accredited investors (generally those with assets in excess of $1,000,000 or annual income exceeding $200,000 or $300,000 together with their spouse). These regulations, if they apply, require the delivery, prior to any transaction involving a penny stock, of a disclosure schedule explaining the penny stock market and the associated risks. Under these regulations, certain brokers who recommend such securities to persons other than established customers or certain accredited investors must make a special written suitability determination regarding such a purchaser and receive such purchaser’s written agreement to a transaction prior to sale. These regulations may have the effect of limiting the trading activity of our common stock, reducing the liquidity of an investment in our common stock and increasing the transaction costs for sales and purchases of our common stock as compared to other securities. The stock market in general and the market prices for penny stock companies in particular, have experienced volatility that often has been unrelated to the operating performance of such companies. These broad market and industry fluctuations may adversely affect the price of our stock, regardless of our operating performance.  Stockholders should be aware that, according to Securities and Exchange Commission (“SEC”) Release No. 34-29093, the market for penny stocks has suffered in recent years from patterns of fraud and abuse. Such patterns include 1) control of the market for the security by one or a few broker-dealers that are often related to the promoter or issuer; 2) manipulation of prices through prearranged matching of purchases and sales and false and misleading press releases; 3) boiler room practices involving high-pressure sales tactics and unrealistic price projections by inexperienced sales persons; 4) excessive and undisclosed bid-ask differential and markups by selling broker-dealers; and 5) the wholesale dumping of the same securities by promoters and broker-dealers after prices have been manipulated to a desired level, along with the resulting inevitable collapse of those prices and with consequent investor losses. The occurrence of these patterns or practices could increase the volatility of our share price.

We may not be able to attract the attention of major brokerage firms, which could have a material adverse impact on the market value of our common stock.  Security analysts of major brokerage firms may not provide coverage of our common stock since there is no incentive to brokerage firms to recommend the purchase of our common stock. The absence of such coverage limits the likelihood that an active market will develop for our common stock. It will also likely make it more difficult to attract new investors at times when we require additional capital.

We may be unable to list our common stock on NASDAQ or on any securities exchange. Although we may apply to list our common stock on NASDAQ or the American Stock Exchange in the future, we cannot assure you that we will be able to meet the initial listing standards, including the minimum per share price and minimum capitalization requirements, or that we will be able to maintain a listing of our common stock on either of those or any other trading venue. If our common stock begins trading, until such time as we would qualify for listing on NASDAQ, the American Stock Exchange or another trading venue, our common stock would trade on OTC Markets or OTC Bulletin Board or another over-the-counter quotation system where an investor may find it more difficult to dispose of shares or obtain accurate quotations as to the market value of our common stock. In addition, rules promulgated by the SEC impose various practice requirements on broker-dealers who sell securities that fail to meet certain criteria set forth in those rules to persons other than established customers and accredited investors.  Consequently, if our common stock begins trading, these rules may deter broker-dealers from recommending or selling our common stock, which may further affect the liquidity of our common stock. It would also make it more difficult for us to raise additional capital.

Future sales and issuances of our equity securities could put downward selling pressure on our securities, and adversely affect the stock price. There is a risk that this downward pressure may make it impossible for an investor to sell his or her securities at any reasonable price, if at all. Future sales of substantial amounts of our equity securities in the public market, or the perception that such sales could occur, could put downward selling pressure on our securities, and adversely affect the market price of our common stock.

Conversion of our convertible notes into common stock could result in additional dilution to our stockholders. We have issued convertible notes which are convertible into shares of our common stock at conversion prices which are at a discount to the then current trading price of our common stock. Additionally, upon the occurrence of certain events of default (including conditions outside of our control) the note holders are entitled to increased repayment and interest rates, as well as other remedies. The note holders have anti-dilution and conversion reset provisions which are triggered by the issuance of lower priced securities. The Company has issued a significant number of shares of common stock as a result of the conversion of these convertible notes and expects to continue to issue a significant number of shares in the future. A significant portion of these additional share issuances resulted from the conversion of convertible notes. As shares of our common stock are issued due to the conversion of some or all of the convertible notes in the future, the ownership interests of existing stockholders will continue to be diluted and such dilution is expected to be significant.

10

Events of Default under our convertible notes could result in a judgment against the Company and a foreclosure on all of our assets. We have issued convertible notes which have remedies to the note holder which include a confession of judgment against us in the event of a default. We are currently in default under these convertible notes for our failure to timely file our public reports with the Securities and Exchange Commission. The exercise of rights by the note holder for this event of default could result in a judgment against us and the foreclosure upon all of our assets which would have a material adverse effect on the Company and the price of its shares.

The Company’s common stock was the subject of an unauthorized spam stock promotion. In April 2014, the Company was made aware of spam stock promotion regarding shares of the Company. The Company received complaints, and was forwarded emails and links to social media sites, relating to unsolicited messages containing false and misleading information regarding the Company and its stock price. The spam mails touted RCHA as "the opportunity of the year" that could go past "2 or 3 dollars". The Company did not, and does not, authorize, endorse or sponsor these illegal spam stock promotions or any of the information contained in the emails. However, the spam stock promotions caused the OTC Markets to place a skull and crossbones next to the Company’s stock symbol on the OTC Markets website warning investors with respect to the Company’s stock, and may have caused reputational damage to the Company and its stock. The Company does not have the ability to stop or restrict any future spam stock promotions which may occur and any such future promotions could have an adverse effect on the Company and its share price.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None

Item 6. Exhibits

Exhibit Number	Description of Exhibit
31.1	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101**	The following materials from our Quarterly Report on Form 10-Q for the quarter ended September 30, 2016 formatted in Extensible Business Reporting Language (XBRL).

**Provided herewith

11

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Rich Pharmaceuticals, Inc.
Date:	November 21, 2016
	By: /s/ Ben Chang Ben Chang Title: Chief Executive Officer and Director

12

EX-31.1

CERTIFICATIONS

I, Ben Chang, certify that;

1. I have reviewed this quarterly report on Form 10-Q for the quarter ended September 30, 2016 of Rich Pharmaceuticals, Inc. (the “registrant”);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 21, 2016

/s/ Ben Chang

By: Ben Chang

Title: Chief Executive Officer

EX-31.2

CERTIFICATIONS

I, Ben Chang, certify that;

1. I have reviewed this quarterly report on Form 10-Q for the quarter ended September 30, 2016 of Rich Pharmaceuticals, Inc. (the “registrant”);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 21, 2016

/s/ Ben Chang

By: Ben Chang

Title: Chief Financial Officer

EX-32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND

CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly Report of Rich Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2016 filed with the Securities and Exchange Commission (the “Report”), I, Ben Chang, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the consolidated financial condition of the Company as of the dates presented and the consolidated result of operations of the Company for the periods presented.

By:	/s/ Ben Chang
Name:	Ben Chang
Title:	Principal Executive Officer, Principal Financial Officer and Director
Date:	November 21, 2016

This certification has been furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

XML

Document and Entity Information - shares	6 Months Ended
	Sep. 30, 2016	Nov. 03, 2016
Document And Entity Information
Entity Registrant Name	Rich Pharmaceuticals, Inc.
Entity Central Index Key	0001504389
Document Type	10-Q
Document Period End Date	Sep. 30, 2016
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		960,815,966
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2016

XML

Condensed Balance Sheets - USD ($)	Sep. 30, 2016	Mar. 31, 2016
Current Assets
Cash and equivalents
Prepaid expenses		2,800
Total Current Assets		2,800
Property and equipment, net	2,869	3,731
TOTAL ASSETS	2,869	6,531
Current Liabilities
Bank overdraft	2,148	2,948
Accounts payable	350,730	1,139,431
Accrued expenses	761,111	530,150
Due to related parties	39,100	76,913
Note payable	900,000
Convertible notes payable, net of debt discount	437,428	201,879
Derivative liabilities	270,531	446,912
Total Current Liabilities	2,761,048	2,398,233
Long-term Liabilities
Convertible notes payable, net of debt discount
Derivative liabilities
Total Long-term Liabilities
Total Liabilities	2,761,048	2,398,233
Stockholders Deficit
Preferred stock, $.001 par value, 10,000,000 shares authorized, 6,000,000 shares issued and outstanding, respectively	6,000	6,000
Common stock, $0.001 par value, 4,000,000,000 shares authorized, 640,739,418 and 216,364,262 shares issued and outstanding,	640,736	216,364
Additional paid-in capital	6,243,408	6,589,374
Accumulated deficit	(9,648,323)	(9,203,440)
Total Stockholders Deficit	(2,758,179)	(2,391,702)
TOTAL LIABILITIES AND STOCKHOLDERS DEFICIT	$ 2,869	$ 6,531

XML

Condensed Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2016	Mar. 31, 2016	Sep. 06, 2013	Sep. 05, 2013
Statement of Financial Position [Abstract]
Common Stock, Par Value	$ .001	$ .001	$ 0.001	$ 0.001
Common Stock, Shares Authorized	4,000,000,000	4,000,000,000	375,030,000	900,000
Common Stock, Issued	640,739,418	216,364,262
Preferred Stock, Par Value	$ .001	$ .001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Issued	6,000,000	6,000,000

XML

Condensed Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Income Statement [Abstract]
REVENUES
OPERATING EXPENSES
Consulting expenses	5,850		16,075	6,000
Office expenses	35,472	25,140	70,046	45,894
Depreciation expense	431	118	862	237
Wages and taxes	96,001	91,071	191,956	182,793
Professional fees	34,158	26,338	88,401	92,285
Regulatory fees	2,686	15,580	9,529	17,249
Research and development		2,000		9,000
Stock-based compensation		62,301		192,392
Travel, meals and entertainment	8,197	11,980	21,403	14,592
TOTAL OPERATING EXPENSES	182,795	234,528	398,272	560,442
LOSS FROM OPERATIONS	(182,795)	(234,528)	(398,272)	(560,442)
OTHER INCOME (EXPENSE)
Amortization of debt discount	(25,786)	(101,837)	(72,360)	(270,988)
Change in value of derivative liability	51,683	180,446	168,454	230,186
Derivative expense		(142,073)		(335,244)
Interest expense	(109,466)	(11,082)	(142,475)	(20,255)
Interest expense related party	(155)	(150)	(230)	(224)
Other Income Total	(83,724)	(74,696)	(46,611)	(396,525)
LOSS BEFORE PROVISION FOR INCOME TAXES	(266,519)	(309,224)	(444,883)	(956,967)
PROVISION FOR INCOME TAXES
NET LOSS	$ (266,519)	$ (309,224)	$ (444,883)	$ (956,697)
NET LOSS PER SHARE: BASIC AND DILUTED	$ (0.00)	$ (0.01)	$ (0.00)	$ (0.02)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: BASIC AND DILUTED	461,006,135	35,569,186	398,719,073	56,827,068

XML

Condensed Statements of Cash Flows - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss for the period	$ (266,519)	$ (309,224)	$ (444,883)	$ (956,697)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expense	431	118	862	237	$ 799
Amortization of debt discount	25,786	101,837	72,360	270,988
Change in value of derivative liability	(51,683)	(180,446)	(168,454)	(230,186)
Derivative expense		(142,073)		(335,244)
Interest converted into stock			5,416
Warrants issued for services				13,259
Stock-based compensation		62,301		192,392
Changes in operating assets and liabilities:
Decrease in prepaid expenses			2,800	5,485
Increase (decrease) in bank overdraft			(800)	484
Increase (decrease) in accounts payable			111,299	531
Increase in accrued expenses			230,961	137,398
Net Cash Used by Operating Activities			(190,438)	(231,136)
CASH FLOWS FROM FINANCING ACTIVITIES:
Loans received (repaid) from/to related parties			(37,812)	30,417
Proceeds from sale of common stock and warrants				50,873
Proceeds from issuance of convertible notes payable			228,250	133,954
Net Cash Provided by Financing Activities			190,438	215,244
Net Increase (Decrease) in Cash and Cash Equivalents				(15,892)
Cash and cash equivalents, beginning of period				15,892	15,892
Cash and cash equivalents, end of period
SUPPLEMENTAL CASH FLOW INFORMATION:
Interest paid
Income taxes paid
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING INFORMATION:
Accounts payable converted into note payable			900,000
Original issue discounts recorded on notes payable				5,400
Debt discounts recorded on convertible notes payable				330,902
Debt/interest converted into common stock and contributed capital			$ 70,478	$ 308,451

XML

Summary of Significant Accounting Policies

6 Months Ended

Sep. 30, 2016

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Nature of Business

On August 9, 2010 the Company was incorporated as Nepia Inc. in the State of Nevada. From August 9, 2010 to July 18, 2013, the Company was in the business of developing, manufacturing, and selling small boilers aimed at farmers primarily in Southeast Asia. Beginning on July 19, 2013, the Company acquired bio-pharmaceutical intellectual property for the treatment of acute myeloid leukemia (AML) and is entering into phase II human studies. The goal is to perfect this indication for marketing purposes for distribution world-wide. On August 26, 2013, as a consequence of our new business direction, the Company changed its name to Rich Pharmaceuticals, Inc. (“Rich” or “the Company”).

On July 18, 2013, the Company designated, from our 10,000,000 authorized shares of preferred stock, par value $0.001, 6,000,000 shares of Series “A” Preferred Stock. Our Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class.

On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 827,670 common shares, and 6,000,000 Series “A” Preferred shares. The common and preferred shares were valued at $123,973. The Company further agreed to use its best efforts to complete a financing resulting in proceeds of at least $2,000,000. If the Company was unable to raise $400,000 according to the terms of the Assignment Agreement, the patent reverts back to Imagic, LLC and its principals. On January 17, 2014, the right of reversion was terminated in exchange for a payment of $20,000.

On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with our boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. In consequence to the Sale Agreement two former officers sold 5,312,925 common shares held by them to our new officer/director. In turn, our new officer/director agreed to cancel 5,002,554 of those shares he received and returned them to treasury for retirement. Certain other shareholders also agreed to cancel 2,625,210 common shares.

On September 5, 2013, the Company increased the authorized common shares, par value $0.0010, from 900,000 shares to 375,030,000 shares. Correspondingly, the Company affirmed a forward split of 4.167 for 1 in which each shareholder was issued 4.167 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split.

Effective February 11, 2016, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 100 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods.

Cash and Cash Equivalents

The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents. At September 30, 2016 and March 31, 2016 the Company had $- and $-, respectively, of unrestricted cash.

Basis of Presentation

The financial statements of the Company have been prepared using the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America and are presented in U.S. dollars. The Company has adopted a March 31 fiscal year end.

Certain information and note disclosures normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These condensed financial statements should be read in conjunction with a reading of the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2016, as filed with the U.S. Securities and Exchange Commission.

Property and Equipment

Property and equipment is recorded at cost and is depreciated using the straight-line method over the estimated useful lives of the related assets. The useful lives of the assets are as follows: Computer equipment, 3 years.

Long-Lived and Intangible Assets

The Company accounts for long-lived and intangible assets in accordance with ASC Topic 360-10-05, “Accounting for the Impairment or Disposal of Long-Lived Assets.” ASC Topic 360-10-05 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the historical cost carrying value of an asset may no longer be appropriate. The Company assesses recoverability of the carrying value of an asset by estimating the future net cash flows expected to result from the asset, including eventual disposition. If the future net cash flows are less than the carrying value of the asset, an impairment loss is recorded equal to the difference between the asset’s carrying value and fair value or disposable value. As of March 31, 2014, the Company fully impaired their intangible assets to $0. During the year ended March 31, 2015, the Company acquired another intangible asset from a related party and valued it at the cost of the intangible to the related party totaling $82,120. As of March 31, 2015, the Company fully impaired their intangible assets to $0.

Fair Value of Financial Instruments

The Company’s financial instruments consist of cash and cash equivalents, prepaid expenses, accounts payable, accrued expenses, amounts due to related parties, stock deposits, and a convertible note payable. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements.

Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability. The guidance establishes three levels of inputs that may be used to measure fair value:

Level 1 – Observable inputs such as quoted prices in active markets;

Level 2 – Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly;

Level 3 – Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The Company did not have any level 1 or level 3 financial instruments at September 30, 2016 or March 31, 2016. As of September 30, 2016, the derivative liabilities were considered a level 2 item; see Note 8.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Income Taxes

Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.

Revenue Recognition

The Company will recognize revenue when products are fully delivered or services have been provided and collection is reasonably assured.

Research and Development

The Company will charge research and development costs to expense when incurred. The research and development costs include payments made to unrelated third party vendors for their work on enhancements to existing technology, or research into new potentially patentable products or processes.

Stock-Based Compensation

Stock-based compensation is accounted for at fair value in accordance with ASC Topic 718. On September 6, 2013, the Company approved the adoption of Rich Pharmaceuticals, Inc. 2013 Stock Option/Stock Issuance Plan (the "2013 Plan”). The 2013 Plan is intended to aid in recruiting and retaining key employees, directors or consultants and to motivate them by providing incentives through the granting of awards of stock options or other stock based awards. The 2013 Plan is administered by the board of directors. Directors, officers, employees and consultants and our affiliates are eligible to participate under the 2013 Plan. A total of 3,900,048 common shares have been reserved for awards under the 2013 Plan. During the year ended March 31, 2015, the Company granted 197,500 stock options to officers, directors, employees and consultants. During the period ended March 31, 2016, the Company granted 3,900,003 stock options to officers, directors, employees and consultants. The Company made the following modifications to the exercise prices of its options: January 12, 2015, the Company modified the exercise price on all outstanding stock options to $0.17; April 6, 2015, the Company modified the exercise price on all outstanding stock options to $0.08 per share; August 4, 2015, the Company modified the exercise price on all outstanding stock options to $0.01 per share.

Basic Loss Per Share

The basic earnings (loss) per share is calculated by dividing the Company’s net income available to common shareholders by the weighted average number of common shares during the year. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity.

Recent Accounting Pronouncements

The Company does not expect the adoption of any other recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

XML

Property and equipment

6 Months Ended

Sep. 30, 2016

Property, Plant and Equipment [Abstract]

Property and equipment

Property and equipment, recorded at cost, consisted of the following as of September 30, 2016 and March 31, 2016:

	September 30, 2016			March 31, 2016
Computer equipment & furniture	$	5,160		$	5,160
Less: accumulated depreciation		(2,291	)		(1,429	)
Property and equipment, net	$	2,869		$	3,731

The useful life of the computer equipment and furniture is 3 years.

Depreciation expense was $863 and $799 for the periods ended September 30, 2016 and March 31, 2016, respectively.

XML

Intangible Assets

6 Months Ended

Sep. 30, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 827,670 common shares and 6,000,000 Series “A” Preferred Stock. These shares were valued at a total of $123,973. The Company has also paid additional funds to third parties to further the development of this asset and terminate the right of reversion totaling $45,000. The Company analyzed the assets at March 31, 2014 and determined that the value could not be supported and impaired the assets to $0.

On October 6, 2014, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Compositions and methods of use of Phorbol Esters for the treatment of Hodgkin’s Lymphoma”, and all related intellectual property, inventions and trade secrets, data and clinical study results. In consideration for the intellectual property the Company issued 2,207,920 common shares. These shares were valued at a total of $7,904,355; however, since the asset was acquired from a related party the Company valued the asset at the cost of the asset to the related party, $82,120, and treated the excess value as a deemed dividend reducing additional paid in capital. The Company analyzed the assets at March 31, 2015 and determined that the value could not be supported and impaired the assets to $0.

XML

Accrued Expenses

6 Months Ended

Sep. 30, 2016

Payables and Accruals [Abstract]

Accrued Expenses

Accrued expenses consisted of the following as of September 30, 2016 and March 31, 2016:

	September 30, 2016		March 31, 2016
Wages and taxes	$	703,756	$	514,713
Accrued interest		57,355		15,437
Total accrued expenses	$	761,111	$	530,150

XML

Related Party Debt and Transactions

6 Months Ended

Sep. 30, 2016

Related Party Transactions [Abstract]

Related Party Debt and Transactions

On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with its boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital.

During the year ended March 31, 2015 and 2014, the Company received loans from companies controlled by its new CEO or shareholders totaling $5,000 and $36,000, respectively. The loans are unsecured, non-interest bearing with no specific terms of repayment. The Company repaid all $41,000 of the loans during the year ended March 31, 2015.

Also during the year ended March 31, 2015, the Company received a $6,000 loan from a shareholder. During the period ended September 30, 2016 the Company received an additional $6,280 from this related party. The loan is unsecured and bears 8% interest. There is a total due of $12,280 as of September 30, 2016. Interest accrued on the note as of September 30, 2016 was $597. The Company is in default on the balance of this note.

During the period ending March 31, 2016, the Company received $22,200 in unsecured non-interest bearing loans from related parties and during the period ending September 30, 2016 received an additional $3,100, and has repaid $25,300 of these loans leaving a total due of $- as of September 30, 2016. These loans are deemed to be short-term and are payable at the discretion of the Company.

On September 6, 2013, the Company entered into an Employment Agreement with our Chief Executive Officer, Chief Financial Officer, President and Secretary. The Employment Agreement provides for a term of two years; annual compensation of $275,000, a signing bonus of $68,750, and options to purchase up to 30,002 shares of common stock at an exercise price of $2.00 per share. The CEO earned $137,500 and $275,000 for the periods ended September 30, 2016 and March 31, 2016 (respectively) as a result of this agreement, these amounts contribute to the $531,362 and $395,630 of officer compensation which is included in accrued expenses, as of September 30, 2016 and March 31, 2016.

XML

Note Payable

6 Months Ended

Sep. 30, 2016

Debt Disclosure [Abstract]

Note Payable

On August 13, 2014, the Company issued a convertible note payable in the amount of $61,111 including an original issue discount of $5,500. The note has a one-time 12% interest charge and is due on August 14, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $61,111 of principal and $6,266 of interest into 1,403,700 shares of common stock leaving a remaining balance of $0. During the year ended March 31, 2016, the note holder converted $1,067 of interest into 177,836 shares of common stock leaving a remaining balance of accrued interest of $0 as of March 31, 2016.

On September 18, 2014, the Company issued a convertible note payable in the amount of $64,500 including an original issue discount of $5,500. The note bears a one-time 12% interest charge and is due on September 18, 2015. The loan becomes convertible immediately upon the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. However, if the market price during the 20 day trading period (mentioned above) is below $0.03, then the conversion factor will be reduced to 55%. During the year ended March 31, 2015, the note holder converted $10,000 of principal into 181,819 shares of common stock leaving a remaining balance of $54,500. During the period ending March 31, 2016 the note holder converted $54,500 in principal and $8,240 in accrued interest into 1,879,597 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016.

On September 23, 2014, the Company issued a convertible note payable in the amount of $55,000. The note bears 8% interest and is due on June 23, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty-five (25) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $25,200 of the principle into 700,000 common shares leaving a remaining balance of $29,800. During the period ending March 31, 2016 the note holder converted $29,800 in principal and $2,158 in accrued interest into 864,672 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016.

On October 6, 2014, the Company issued a convertible promissory note in the amount of $33,000. The note is due on July 6, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $33,000 in principal and $1,320 in accrued interest into 780,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016.

On November 6, 2014, the Company issued a convertible promissory note in the amount of $55,000. The note is due on May 6, 2015 and bears interest at 12% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 52.5% multiplied by lowest daily market price, for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $55,000 in principal and $3,553 in accrued interest into 2,813,634 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016.

On November 25, 2014, the Company issued a convertible promissory note in the amount of $43,000. The note is due on August 28, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder assessed a default fee of $3,510 to increase the balance of the note and also converted $46,510 in principal into 5,290,270 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016.

On December 16, 2014, the Company issued a convertible note payable in the amount of $33,333 including an original issue discount of $3,333. The note bears a one-time 12% interest charge and is due on December 16, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $33,333 in principal and $4000 in accrued interest into 5,047,167 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016.

On January 9, 2015, the Company issued a convertible promissory note in the amount of $33,000. The note is due on October 13, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder assessed a default fee of $16,500 to increase the balance of the note and also converted $49,500 in principal and $1,320 in interest into 8,470,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016.

On February 5, 2015, the Company issued a convertible promissory note in the amount of $54,000. The note is due on November 9, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $33,020 in principal into 12,393,030 shares of common stock, and incurred a default fee of $27,000 leaving a remaining balance of $47,980. Interest accrued on this note as of September 30, 2016 is $5,579. The Company is in default on the balance of this note.

On February 17, 2015, the Company issued a convertible note payable in the amount of $66,780 including an original issue discount of $6,780. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $66,780 in principal and $3,148 in accrued interest into 8,854,031 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016.

On February 25, 2015, the Company issued a convertible note payable in the amount of $27,778 including an original issue discount of $2,778. The note bears a one-time 12% interest charge and is due on February 25, 2017. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $27,778 in principal and $3,333 in accrued interest into 5,185,210 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016.

On March 9, 2015, the Company issued a convertible note payable in the amount of $55,000. The note bears 8% interest and was originally due on December 9, 2015, with a revised due date of June 23, 2017. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty-five (25) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $38,785 in principal and $5,135 in accrued interest into 57,733,852 shares of common stock. During the period ending June 30, 2016 the note holder converted $7,377 in principal and $422 in accrued interest into 46,484,586 shares of common stock leaving a remaining balance of $ 8,838. Accrued interest was $178 as of September 30, 2016.

On March 26, 2015, the Company issued a convertible note payable in the amount of $29,680 including an original issue discount of $1,680. The note bears 8% interest and is due on March 23, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) days prior to the conversion date. During the period ending March 31, 2016 the note holder converted $10,929 in principal into 15,924,728 shares of common stock leaving a remaining balance of $18,751. Accrued interest was $4,520 as of September 30, 2016. The Company is in default on the balance of this note.

On March 2, 2015, the Company issued a convertible note payable in the amount of $58,300 including an original issue discount of $3,300. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible immediately at the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twenty-two (22) trading day period ending on the latest complete trading day prior to the conversion date. On March 2, 2015 the note holder converted $56,402 of the principle into 1,215,551 common shares leaving a remaining balance of $1,898. During the period ending March 31, 2016 the note holder converted $1,898 in principal and $20 in accrued interest into 53,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016.

On May 5, 2015, the Company issued a convertible note payable in the amount of $68,900 including an original issue discount of $3,900. The note bears 8% interest and is due on May 5, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 42% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. . During the period ending March 31, 2016 the note holder converted $8,461 in principal and $566 in accrued interest into 18,135,267 shares of common stock. During the period ending September 30, 2016 the note holder converted $25,939 in principal and $2,675 in accrued interest into 224,358,188 shares of common stock leaving a remaining balance of $34,500. Accrued interest was $3,951 as of September 30, 2016.

On May 6, 2015, the Company issued a convertible note payable in the amount of $10,500. The note bears 8% interest and is due on February 8, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the thirty (30) trading day period ending on the latest complete trading day prior to the conversion date. The Company incurred a default fee of $5,250, leaving a balance of $15,750 as of September 30, 2016. Interest accrued on this note as of September 30, 2016 is $1,451. The Company is in default on the balance of this note.

On May 27, 2015, the Company issued a convertible note payable in the amount of $16,500. The note bears 8% interest rate and is due on May 28, 2016. The loan becomes convertible on May 27, 2015, the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $16,500 in principal and $344 in accrued interest into 2,591,323 shares of common stock leaving a remaining balance of $0. Interest accrued as of March 31, 2016 is $0.

On August 28, 2015, the Company issued a convertible note payable in the amount of $15,000. The note bears 8% interest and is due on August 28, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending September 30, 2016 the note holder converted $15,000 in principal and $939 in accrued interest into 87,032,383 shares of common stock leaving a remaining balance of $0.

On September 4, 2015, the Company issued a convertible note payable in the amount of $19,000. The note bears 8% interest and is due on June 4, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the fifteen (15) trading day period ending on the latest complete trading day prior to the conversion date. The loan balance as of September 30, 2016 is $19,000, and interest accrued as of September 30, 2016 is $1,632.

On December 29, 2015, the Company issued a convertible note payable in the amount of $57,378. The note bears 8% interest rate and was originally due on December 30, 2016, with a revised due date of June 23, 2017. The loan becomes convertible on December 29, 2015, the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $59,934 in principal and $1,222 in accrued interest into 35,927,887 shares of common stock, and incurred a default penalty of $4,165, leaving a remaining balance of $1,609. Interest accrued as of September 30, 2016 is $51.

On January 22, 2016, the Company issued a convertible note payable in the amount of $60,500. The note bears 10% interest and is due on October 22, 2016. The loan becomes convertible on January 22, 2016. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. Interest accrued as of September 30, 2016 is $4,177.

On February 25, 2016, the Company issued a convertible note payable in the amount of $27,500. The note bears 8% interest rate and is due on February 25, 2017. The loan becomes convertible on February 25, 2016, the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date..During the period ending September 30, 2016 the note holder converted $16,745 in principal and $1,380 in interest into 66,500,000 shares of common stock leaving a remaining balance of $10,755. Interest accrued as of September 30, 2016 is $217. This loan has an unamortized original issue discount of $836 as of the end of the period.

On March 24, 2016, the Company issued a convertible note payable in the amount of $7,500. The note bears 8% interest rate and is due on March 24, 2017. The loan becomes convertible on March 24, 2016, the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. Interest accrued as of September 30, 2016 is $312.

On May 25, 2016, the Company issued a convertible note payable in the amount of $30,000. The note bears 8% interest and is due on May 25, 2017. The loan becomes convertible 180 days after issuance or November 21, 2016. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. Interest accrued as of September 30, 2016 is $842.

On June 8, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $84,250. The note bears interest at the rate of 8% and must be repaid on or June 8, 2017. The note and any accrued interest may be converted into shares of Company common stock at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion. Interest accrued as of September 30, 2016 is $2,105.

On June 23, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $56,000. The note bears interest at the rate of 8% and must be repaid on or June 23, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion. Interest accrued as of June 30, 2016 is $1,215.

On July 7, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $58,000. The note bears interest at the rate of 8% and must be repaid on or July 7, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, 180 days after issuance or January 3, 2017, at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion. Interest accrued as of September 30, 2016 is $1,043.

XML

Convertible Note Payable

6 Months Ended

Sep. 30, 2016

Debt Disclosure [Abstract]

Convertible Note Payable

On August 13, 2014, the Company issued a convertible note payable in the amount of $61,111 including an original issue discount of $5,500. The note has a one-time 12% interest charge and is due on August 14, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $61,111 of principal and $6,266 of interest into 1,403,700 shares of common stock leaving a remaining balance of $0. During the year ended March 31, 2016, the note holder converted $1,067 of interest into 177,836 shares of common stock leaving a remaining balance of accrued interest of $0 as of March 31, 2016.

On September 18, 2014, the Company issued a convertible note payable in the amount of $64,500 including an original issue discount of $5,500. The note bears a one-time 12% interest charge and is due on September 18, 2015. The loan becomes convertible immediately upon the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. However, if the market price during the 20 day trading period (mentioned above) is below $0.03, then the conversion factor will be reduced to 55%. During the year ended March 31, 2015, the note holder converted $10,000 of principal into 181,819 shares of common stock leaving a remaining balance of $54,500. During the period ending March 31, 2016 the note holder converted $54,500 in principal and $8,240 in accrued interest into 1,879,597 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016.

On September 23, 2014, the Company issued a convertible note payable in the amount of $55,000. The note bears 8% interest and is due on June 23, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty-five (25) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $25,200 of the principle into 700,000 common shares leaving a remaining balance of $29,800. During the period ending March 31, 2016 the note holder converted $29,800 in principal and $2,158 in accrued interest into 864,672 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016.

On October 6, 2014, the Company issued a convertible promissory note in the amount of $33,000. The note is due on July 6, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $33,000 in principal and $1,320 in accrued interest into 780,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016.

On November 6, 2014, the Company issued a convertible promissory note in the amount of $55,000. The note is due on May 6, 2015 and bears interest at 12% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 52.5% multiplied by lowest daily market price, for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $55,000 in principal and $3,553 in accrued interest into 2,813,634 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016.

On November 25, 2014, the Company issued a convertible promissory note in the amount of $43,000. The note is due on August 28, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder assessed a default fee of $3,510 to increase the balance of the note and also converted $46,510 in principal into 5,290,270 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016.

On December 16, 2014, the Company issued a convertible note payable in the amount of $33,333 including an original issue discount of $3,333. The note bears a one-time 12% interest charge and is due on December 16, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $33,333 in principal and $4000 in accrued interest into 5,047,167 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016.

On January 9, 2015, the Company issued a convertible promissory note in the amount of $33,000. The note is due on October 13, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder assessed a default fee of $16,500 to increase the balance of the note and also converted $49,500 in principal and $1,320 in interest into 8,470,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016.

On February 5, 2015, the Company issued a convertible promissory note in the amount of $54,000. The note is due on November 9, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $33,020 in principal into 12,393,030 shares of common stock, and incurred a default fee of $27,000 leaving a remaining balance of $47,980. Interest accrued on this note as of September 30, 2016 is $5,579. The Company is in default on the balance of this note.

On February 17, 2015, the Company issued a convertible note payable in the amount of $66,780 including an original issue discount of $6,780. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $66,780 in principal and $3,148 in accrued interest into 8,854,031 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016.

On February 25, 2015, the Company issued a convertible note payable in the amount of $27,778 including an original issue discount of $2,778. The note bears a one-time 12% interest charge and is due on February 25, 2017. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $27,778 in principal and $3,333 in accrued interest into 5,185,210 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016.

On March 9, 2015, the Company issued a convertible note payable in the amount of $55,000. The note bears 8% interest and was originally due on December 9, 2015, with a revised due date of June 23, 2017. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty-five (25) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $38,785 in principal and $5,135 in accrued interest into 57,733,852 shares of common stock. During the period ending June 30, 2016 the note holder converted $7,377 in principal and $422 in accrued interest into 46,484,586 shares of common stock leaving a remaining balance of $ 8,838. Accrued interest was $178 as of September 30, 2016.

On March 26, 2015, the Company issued a convertible note payable in the amount of $29,680 including an original issue discount of $1,680. The note bears 8% interest and is due on March 23, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) days prior to the conversion date. During the period ending March 31, 2016 the note holder converted $10,929 in principal into 15,924,728 shares of common stock leaving a remaining balance of $18,751. Accrued interest was $4,520 as of September 30, 2016. The Company is in default on the balance of this note.

On March 2, 2015, the Company issued a convertible note payable in the amount of $58,300 including an original issue discount of $3,300. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible immediately at the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twenty-two (22) trading day period ending on the latest complete trading day prior to the conversion date. On March 2, 2015 the note holder converted $56,402 of the principle into 1,215,551 common shares leaving a remaining balance of $1,898. During the period ending March 31, 2016 the note holder converted $1,898 in principal and $20 in accrued interest into 53,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016.

On May 5, 2015, the Company issued a convertible note payable in the amount of $68,900 including an original issue discount of $3,900. The note bears 8% interest and is due on May 5, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 42% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. . During the period ending March 31, 2016 the note holder converted $8,461 in principal and $566 in accrued interest into 18,135,267 shares of common stock. During the period ending September 30, 2016 the note holder converted $25,939 in principal and $2,675 in accrued interest into 224,358,188 shares of common stock leaving a remaining balance of $34,500. Accrued interest was $3,951 as of September 30, 2016.

On May 6, 2015, the Company issued a convertible note payable in the amount of $10,500. The note bears 8% interest and is due on February 8, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the thirty (30) trading day period ending on the latest complete trading day prior to the conversion date. The Company incurred a default fee of $5,250, leaving a balance of $15,750 as of September 30, 2016. Interest accrued on this note as of September 30, 2016 is $1,451. The Company is in default on the balance of this note.

On May 27, 2015, the Company issued a convertible note payable in the amount of $16,500. The note bears 8% interest rate and is due on May 28, 2016. The loan becomes convertible on May 27, 2015, the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $16,500 in principal and $344 in accrued interest into 2,591,323 shares of common stock leaving a remaining balance of $0. Interest accrued as of March 31, 2016 is $0.

On August 28, 2015, the Company issued a convertible note payable in the amount of $15,000. The note bears 8% interest and is due on August 28, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending September 30, 2016 the note holder converted $15,000 in principal and $939 in accrued interest into 87,032,383 shares of common stock leaving a remaining balance of $0.

On September 4, 2015, the Company issued a convertible note payable in the amount of $19,000. The note bears 8% interest and is due on June 4, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the fifteen (15) trading day period ending on the latest complete trading day prior to the conversion date. The loan balance as of September 30, 2016 is $19,000, and interest accrued as of September 30, 2016 is $1,632.

On December 29, 2015, the Company issued a convertible note payable in the amount of $57,378. The note bears 8% interest rate and was originally due on December 30, 2016, with a revised due date of June 23, 2017. The loan becomes convertible on December 29, 2015, the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $59,934 in principal and $1,222 in accrued interest into 35,927,887 shares of common stock, and incurred a default penalty of $4,165, leaving a remaining balance of $1,609. Interest accrued as of September 30, 2016 is $51.

On January 22, 2016, the Company issued a convertible note payable in the amount of $60,500. The note bears 10% interest and is due on October 22, 2016. The loan becomes convertible on January 22, 2016. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. Interest accrued as of September 30, 2016 is $4,177.

On February 25, 2016, the Company issued a convertible note payable in the amount of $27,500. The note bears 8% interest rate and is due on February 25, 2017. The loan becomes convertible on February 25, 2016, the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date..During the period ending September 30, 2016 the note holder converted $16,745 in principal and $1,380 in interest into 66,500,000 shares of common stock leaving a remaining balance of $10,755. Interest accrued as of September 30, 2016 is $217. This loan has an unamortized original issue discount of $836 as of the end of the period.

On March 24, 2016, the Company issued a convertible note payable in the amount of $7,500. The note bears 8% interest rate and is due on March 24, 2017. The loan becomes convertible on March 24, 2016, the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. Interest accrued as of September 30, 2016 is $312.

On May 25, 2016, the Company issued a convertible note payable in the amount of $30,000. The note bears 8% interest and is due on May 25, 2017. The loan becomes convertible 180 days after issuance or November 21, 2016. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. Interest accrued as of September 30, 2016 is $842.

On June 8, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $84,250. The note bears interest at the rate of 8% and must be repaid on or June 8, 2017. The note and any accrued interest may be converted into shares of Company common stock at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion. Interest accrued as of September 30, 2016 is $2,105.

On June 23, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $56,000. The note bears interest at the rate of 8% and must be repaid on or June 23, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion. Interest accrued as of June 30, 2016 is $1,215.

On July 7, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $58,000. The note bears interest at the rate of 8% and must be repaid on or July 7, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, 180 days after issuance or January 3, 2017, at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion. Interest accrued as of September 30, 2016 is $1,043.

XML

Derivative Liabilities

6 Months Ended

Sep. 30, 2016

Notes to Financial Statements

Derivative Liabilities

In accordance with AC 815, the Company has bifurcated the conversion feature of their convertible notes and recorded a derivative liability on the date each note became convertible. The derivative liability was then revalued on each reporting date.

As detailed in Note 7 (above) the Company has issued several convertible notes in varying amounts and terms, with the following loans becoming convertible during the periods ending September 30, 2016 and March 31, 2016: $33,000 noted dated October 6, 2014; $55,000 note dated November 6, 2014; $43,000 note dated November 25, 2014; $33,000 note dated January 9, 2015; $54,000 note dated February 5, 2015; $66,780 note dated February 17, 2015;$58,300 note dated March 2, 2015; $55,000 note dated March 9, 2015; $29,680 note dated March 26, 2015; $68,900 note dated May 5, 2015; $10,500 note dated May 6, 2015; $16,500 note dated May 27, 2015; $15,000 note dated August 28, 2015; $19,000 note dated September 4, 2015; $55,000 note dated December 29, 2015; $60,500 note dated January 22, 2016; $27,500 note dated February 25, 2016; $7,500 note dated March 24, 2016.

ASC 815 requires Company management to assess the fair market value of certain derivatives at each reporting period and recognize any change in the fair market value as another income or expense item.  The Company’s only asset or liability measured at fair value on a recurring basis is its derivative liability associated with the above convertible debt.  During the period ended September 30, 2016, the Company recorded a total change in the fair market value of the derivative liabilities of $168,454.

The Company uses the Black-Scholes option pricing model to value the derivative liability upon the initial conversion date and at each reporting period.  Included in the model to value the derivative liabilities of the above loans are the following assumptions: stock price at valuation date of $0.0002, exercise price of $0.0001 - $0.000116, dividend yield of zero, years to maturity of 0.060270 – .728770, a risk free rate of 0.29% - 0.59%, and annualized volatility of 284% - 379%. The above loans were all discounted in full with the exception of the March 2, 2015 loan which had a debt discount of $46,370, the May 5, 2015 loan which had an initial debt discount of $41,222, and the May 27, 2015 loan which had an initial debt discount of $15,000. Based on the valuations on the initial valuation dates for the period ending September 30, 2016, the Company recognized debt discounts related to the conversion features totaling $- and a derivative expense of $- related to the excess value of the derivative liabilities. Once the loans are fully converted, the remaining derivative liability is reclassified to equity as additional paid-in capital. As of September 30, 2016, unamortized debt discount, including original issue discounts totaled $16,005. The derivative liabilities totaled $270,531 as of September 30, 2016, of which $- related to long-term debt.

XML

Equity Transactions

6 Months Ended

Sep. 30, 2016

Equity Transactions

Equity Transactions

The Company has 4,000,000,000 common shares authorized with a par value of $ 0.001 per share.

The Company has 10,000,000 preferred shares authorized with a par value of $ 0.001 per share.

On July 18, 2013, the Company designated, from the 10,000,000 authorized shares of preferred stock, 6,000,000 shares of Series “A” Preferred Stock. The Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class.

On July 18, 2013, the Company granted 6,000,000 Series “A” Preferred shares and 827,670 common shares for the intellectual property. The common and preferred shares were valued at a total of $123,973.

On July 19, 2013, our new officer/director agreed to cancel 5,002,554 common shares and returned them to treasury. Certain other shareholders also agreed to cancel 2,625,210 common shares.

On September 5, 2013, the Company increased the authorized common shares from 900,000 to 375,030,000. Correspondingly, the Company affirmed a forward split of 4.167 for 1 in which each shareholder was issued 4.167 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split.

On October 29, 2013, the Company granted 2,500 units at $30.00 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $50.00 and a one year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below.

On December 11, 2013, the Company granted 2,500 units at $30.00 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $50.00 and a one year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below.

On June 9, 2015, the Company issued 900,000 units at $0.02 per unit. Each unit consisted of one common stock warrant with an exercise price of $0.02 and a five year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below

On December 15, 2015, the Company issued 4,000,000 units at $0.01 per unit. Each unit consisted of one common stock warrant with an exercise price of $0.01 and a five year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below.

The following is a summary of the inputs used to determine the value of the warrants issued in connection with common stock using the Black-Scholes option pricing model.

Date	June 9, 2015	Dec 15,2015
Warrants	900,000	4,000,000
Stock price on grant date	$0.02	$0.01
Exercise price	$0.02	$0.01
Expected life	5 year	5 year
Volatility	98%	98%
Risk-free rate	1.74%	1.71%
Calculated value	$13,259	$29,612
Fair value allocation of proceeds	$13,259	$29,612

The following is a summary of the warrant activity for the period March 31, 2016 to September 30, 2016:

	Number of warrants		Weighted average exercise price
Outstanding, March 31, 2016		4,930,666	$	0.192
Granted			$	—
Exercised		—		—
Outstanding, September 30, 2016		4,930,666	$	0.192

On April 22, 2015, the Company sold 100,381 shares of common stock for $5,405 in cash, which was paid directly to a vendor for accounts payable.

On June 25, 2015, the Company sold 1,542,455 shares of common stock for $10,797 in cash, of which $3,750 was paid directly to professionals in connection with the expenses of that sale, and $7,047 was retained by the Company.

On July 7, 2015, the Company sold 1,619,423 shares of common stock for $11,336 in cash, of which $3,750 was paid directly to a vendor for professional services.

On July 15, 2015, the Company sold 1,439,282 shares of common stock for $10,075 in cash.

On October 27, 2015, the Company sold 1,648,840 shares of common stock for $11,542 in cash.

During the periods ended September 30, 2016 and March 31, 2016, the Company received, as listed, conversion notices from various note holders. The Company issued the following common shares to satisfy the conversion of the following debt and interest:

On February 8, 2016, the Company approved a change in the authorized shares of common stock to 4,000,000,000 shares.

Effective February 11, 2016, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 100 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods.

The Company accounts for employee stock-based compensation in accordance with the guidance of ASC Topic 718: Compensation - Stock Compensation, which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values

The Company follows ASC Topic 505-50, formerly EITF 96-18, “Accounting for Equity Instruments that are Issued to Other than Employees for Acquiring, or in Conjunction with Selling Goods and Services,” for stock options and warrants issued to consultants and other non-employees. In accordance with ASC Topic 505-50, these stock options issued as compensation for services provided to the Company are accounted for based upon the fair value of the services provided or the estimated fair market value of the option, whichever can be more clearly determined.

During the year ended March 31, 2014, the Company granted 475,033 stock options to officers, directors, employees and consultants. During the year ended March 31, 2015, the Company granted 197,500 stock options to officers, directors, employees and consultants. During the period ended March 31, 2016, the Company granted 3,900,003 stock options to officers, directors, employees and consultants The options have been re-priced twice as follows: (1) Effective January 12, 2015, the Company approved the re-pricing of all 672,533 previously granted options under the Company’s 2013 Equity Incentive Plan, which had exercise prices between $1.91984 per share and $30.0 per share, to $0.17 per share which was the closing price of the Company’s common stock on January 9, 2015. All of the other terms of the options remained unchanged.

Date	Debt/Interest Converted	Common Stock Issued	Price per Share
April 1, 2015	$16,650	411,111	$0.04050
April 6, 2015	$10,000	209,644	$0.04770
April 8, 2015	$15,309	453,561	$0.03375
April 8, 2015	$20,001	454,545	$0.04400
April 9, 2015	$14,320	325,455	$0.04400
April 14, 2015	$10,000	236,967	$0.04220
April 16, 2015	$1,918	53,000	$0.03619
April 21, 2015	$10,000	259,740	$0.03850
April 29, 2015	$15,000	389,610	$0.03850
May 4, 2015	$5,083	131,464	$0.03866
May 12, 2015	$28,456	903,380	$0.03150
May 20, 2015	$20,199	947,645	$0.02131
May 20, 015	$17,240	783,636	$0.02200
May 27, 2015	$13,568	701,801	$0.01933
May 29, 2015	$15,000	882,353	$0.01700
June 11, 2015	$9,897	942,609	$0.01050
June 16, 2015	$14,100	1,175,000	$0.01200
June 16, 2015	$13,565	1,130,417	$0.01200
June 22, 2015	$7,415	1,235,833	$0.00600
June 22, 2015	$14,384	2,479,924	$0.00580
June 23, 2015	$7,752	1,292,000	$0.00600
September 16, 2015	$7,974	1,772,033	$0.00450
September 28, 2015	$10,000	1,666,667	$0.00600
September 29, 2015	$10,620	1,770,000	$0.00600
October 7, 2015	$2,250	375,000	$0.00600
October 7, 2015	$8,400	1,400,000	$0.00600
October 19, 2015	$9,720	1,620,000	$0.00600
November 2, 2015	$4,424	1,966,124	$0.00225
November 23, 2015	$10,000	1,666,667	$0.00600
November 30, 2015	$16,844	2,591,323	$0.00650
December 9, 2015	$1,746	775,991	$0.00225
December 17, 2015	$5,332	919,319	$0.00580
December 28, 2015	$1,341	596,200	$0.00225
December 28, 2015	$17,700	2,950,000	$0.00600
December 28, 2015	$14,305	2,384,167	$0.00600
December 28, 2015	$14,963	2,579,916	$0.00580
December 29, 2015	$8,395	1,399,167	$0.00600
December 29, 2015	$7,670	1,278,333	$0.00600
December 30, 2015	$6,651	2,956,248	$0.00225
January 1, 2016	$28,500	4,384,615	$0.00650
January 4, 2016	$19,339	3,223,213	$0.00600
January 5, 2016	$8,107	3,603,227	$0.00225
January 6, 2016	$16,070	2,678,333	$0.00600
January 6, 2016	$16,597	2,861,607	$0.00580
February 16 ,2016	$1,424	4,220,400	$0.00034
February 17, 2016	$12,800	8,443,272	$0.00152
February 23, 2016	$4,640	4,218,182	$0.00110
February 23, 2016	$3,086	4,200,871	$0.00073
February 24, 2016	$1,492	4,419,970	$0.00034
February 25, 2016	$3,000	2,638,987	$0.00114
February 25, 2016	$4,640	4,218,182	$0.00110
March 1, 2016	$1,313	5,834,458	$0.00022
March 2, 2016	$4,600	5,831,643	$0.00079
March 2, 2016	$1,650	2,586,410	$0.00064
March 2, 2016	$9,332	11,650,000	$0.00080
March 7, 2016	$2,799	6,546,292	$0.00043
March 11, 2016	$1,924	4,147,500	$0.00046
March 14, 2016	$2,245	7,125,777	$0.00032
March 15, 2016	$3,329	7,454,098	$0.00045
March 15, 2016	$5,210	11,450,000	$0.00046
March 22, 2016	$2,419	8,957,888	$0.00027
March 22, 2016	$2,367	7,200,486	$0.00033
March 22, 2016	$5,315	11,682,000	$0.00046
March 28, 2016	$1,986	8,958,779	$0.00022
March 31, 2016 Total	$602,376	194,603,040

Date	Debt/Interest Converted	Common Stock Issued	Price per Share
April 1, 2016	$2,197	9,766,311	$0.000225
April 4, 2016	$4,847	17,250,000	$0.000281
April 7, 2016	$1,750	9,722,222	$0.000180
April 14, 2016	$4,158	19,250,000	$0.000216
April 15, 2016	$1,318	9,766,222	$0.000135
April 26, 2016	$1,705	12,629,776	$0.000135
May 4, 2016	$2,067	9,718,025	$0.000213
May 31, 2016	$   828	4,600,055	$0.000180
June 2, 2016	$9,120	30,000,000	$0.000304
June 2, 2016	$4,401	29,340,333	$0.000150
June 14, 2016	$5,847	29,235,900	$.0.000200
June 17,2016	$5,691	28,456,150	$0.000200
June 29, 2016	$6,580	21,270,355	$0.000309
August 23, 2016	$2,567	22,129,741	$0.000116
August 29, 2016	$2,570	22,156,120	$0.000116
September 6, 2016	$2,547	21,952,672	$0.000116
September 20, 2016	$2,443	25,267,655	$0.000097
September 26, 2016	$2,946	25,393,448	$0.000116
September 28, 2016	$2,947	25,403,448	$0.000116
September 30, 2016	$3,949	51,066,724	$0.000077
September 30, 2016 Total	$70,478	424,375,157

(2) Effective April 6, 2015, the Company approved the re-pricing of all 2,712,535 previously granted options under the Company’s 2013 Equity Incentive Plan, which had exercise prices between $.08 per share and $0.17 per share, to $0.08 per share which was the closing price of the Company’s common stock on April 6, 2015. All of the other terms of the options remained unchanged. (3) Effective August 4, 2015, the Company approved the re-pricing of all 3,712,535 previously granted options under the Company’s 2013 Equity Incentive Plan, which had exercise prices between $.08 per share and $0.02 per share, to $0.02 per share which was the closing price of the Company’s common stock on August 4, 2015. All of the other terms of the options remained unchanged. The Company revalued all existing options on January 12, 2015 and again on April 6, 2015, and again on August 4, 2015 using the Black-Scholes option pricing model using the initial terms of the options and the modified terms of the options. The difference in the valuations was recorded as additional expense. The re-pricing of the options resulted in the recognition of an additional $50,448 on January 9, 2015 and an additional $9,316 on April 6, 2015, and an additional $47,463 on August 4, 2015 in related stock based compensation expense for those periods.

The following is a summary of the inputs used to determine the value of the options using the Black-Scholes option pricing model.

Date	April 6, 2015	June 9, 2015	December 15, 2015
Options	2,040,003	1,000,000	860,000
Stock price grant date	$0.08	$0.02	$0.01
Initial Exercise price	$0.08	$0.02	$0.01
Modified Exercise price	$0.01	$0.01	$0.01
Expected life	5.0	5.0	5.0
Volatility	99%	99%	84%
Risk-free rate	1.31%	1.74%	1.70%
Calculated value	$120,778	$14,838	$5,736
Modified value	$151,221	$16,347	$5,736

The following is a summary of the option activity for the period March 31, 2015 through September 30, 2016:

	Number of options	Weighted average exercise price
Outstanding, March 31, 2015	672,533	$0.01
Granted	3,900,003	$0.01
Exercised	-	-
Expired	-	-
Outstanding, September 30, 2016	4,572,536	$0.01

XML

Commitments and Contigencies

6 Months Ended

Sep. 30, 2016

Accounting Policies [Abstract]

Commitments and Contingencies

The Company leases office space on a verbal month-to-month agreement. Monthly rent is approximately $2,800.

On July 8, 2016, the Company engaged a foreign based company to evaluate the safety and efficacy of RP-323 over a 27 month period. The contract stipulates a commitment of $193,255 with additional fees for pass-through expenses.

The inventor of the intellectual property which was assigned to Rich Pharmaceuticals, Inc. in July 2013 by Imagic, LLC and Richard L. Chang’s Holdings, LLC is presently in declaratory relief litigation with Biosuccess Biotech, Co. LTD. (“Biosuccess”), a company who was previously assigned licensing rights in the intellectual property. In connection with this litigation, on January 17, 2014, the Company received notice of a complaint filed by Biosuccess against the Company, Imagic, LLC, Richard L. Chang’s Holdings, LLC, and Ben Chang (our CEO and a director) in the United States District Court, Central District of California Western Division (the “District Court”). The Complaint includes allegations of patent and copyright infringement, misappropriation of trade secrets, breach of fiduciary duty, unfair competition and other causes of actions against the Company, Imagic, LLC, Richard L. Chang’s Holdings, LLC, and Ben Chang (the “Litigation”). The Complaint seeks relief which includes compensatory damages, attorneys’ fees and costs, an award of treble damages, and such other relief as the court may deem just and proper. As previously disclosed on January 4, 2016, the Litigation has been settled through a confidential mediation process supervised by the Federal Court and the Litigation has been dismissed with prejudice by the Federal Court. The Company incurred substantial fees in defending the litigation.

XML

Liquidity and Going Concern

6 Months Ended

Sep. 30, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Liquidity and Going Concern

The Company has a working capital deficit, has not yet received revenues from sales of products or services, and has incurred losses since inception. These factors create substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern.

The ability of the Company to continue as a going concern is dependent on the Company generating cash from the sale of its common stock and/or obtaining debt financing and attaining future profitable operations. Management’s plans include selling its equity securities and obtaining debt financing to fund its capital requirement and ongoing operations; however, there can be no assurance the Company will be successful in these efforts.

XML

Subsequent Events

6 Months Ended

Sep. 30, 2016

Accounting Policies [Abstract]

Subsequent Events

On October 7, 2016, the Company converted $3,035 in principle and $346 in interest on a convertible note payable into 58,291,551 shares of common stock.

On October 14, 2016, the Company converted $3,030 in principle and $350 in interest on a convertible note payable into 58,275,689 shares of common stock.

On October 21, 2016, the Company converted $3,033 in principle and $355 in interest on a convertible note payable into 58,355,689 shares of common stock.

On October 26, 2016, the Company converted $3,025 in principle and $358 in interest on a convertible note payable into 58,316,551 shares of common stock.

On October 20, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $58,000. The note bears interest at the rate of 8% and must be repaid on or October 20, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, 180 days after issuance or January 3, 2017, at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion.

On October 28, 2016, the Company issued an 8% convertible redeemable promissory note in the principal amount of $32,000. The note must be repaid on or before October 20, 2017. The note and any accrued interest may be converted by the lender into shares of Company common stock 180 days after issuance or April 26, 2017, at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion.

On November 7, 2016, the Company converted $5,015 of debt and interest on a convertible note payable into 86,472,931 shares of common stock. 

In accordance with ASC 855-10, the Company has analyzed its operations subsequent to September 30, 2016 to the date these financial statements were issued, and has determined that it does not have any material subsequent events to disclose in these financial statements other than the events described above.

XML

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Sep. 30, 2016

Accounting Policies [Abstract]

Nature of Business

On August 9, 2010 the Company was incorporated as Nepia Inc. in the State of Nevada. From August 9, 2010 to July 18, 2013, the Company was in the business of developing, manufacturing, and selling small boilers aimed at farmers primarily in Southeast Asia. Beginning on July 19, 2013, the Company acquired bio-pharmaceutical intellectual property for the treatment of acute myeloid leukemia (AML) and is entering into phase II human studies. The goal is to perfect this indication for marketing purposes for distribution world-wide. On August 26, 2013, as a consequence of our new business direction, the Company changed its name to Rich Pharmaceuticals, Inc. (“Rich” or “the Company”).

On July 18, 2013, the Company designated, from our 10,000,000 authorized shares of preferred stock, par value $0.001, 6,000,000 shares of Series “A” Preferred Stock. Our Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class.

On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 827,670 common shares, and 6,000,000 Series “A” Preferred shares. The common and preferred shares were valued at $123,973. The Company further agreed to use its best efforts to complete a financing resulting in proceeds of at least $2,000,000. If the Company was unable to raise $400,000 according to the terms of the Assignment Agreement, the patent reverts back to Imagic, LLC and its principals. On January 17, 2014, the right of reversion was terminated in exchange for a payment of $20,000.

On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with our boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. In consequence to the Sale Agreement two former officers sold 5,312,925 common shares held by them to our new officer/director. In turn, our new officer/director agreed to cancel 5,002,554 of those shares he received and returned them to treasury for retirement. Certain other shareholders also agreed to cancel 2,625,210 common shares.

On September 5, 2013, the Company increased the authorized common shares, par value $0.0010, from 900,000 shares to 375,030,000 shares. Correspondingly, the Company affirmed a forward split of 4.167 for 1 in which each shareholder was issued 4.167 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split.

Effective February 11, 2016, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 100 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods.

Cash and Cash Equivalents

The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents. At September 30, 2016 and March 31, 2016 the Company had $- and $-, respectively, of unrestricted cash.

Basis of Presentation

The financial statements of the Company have been prepared using the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America and are presented in U.S. dollars. The Company has adopted a March 31 fiscal year end.

Certain information and note disclosures normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These condensed financial statements should be read in conjunction with a reading of the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2016, as filed with the U.S. Securities and Exchange Commission.

Property and Equipment

Property and equipment is recorded at cost and is depreciated using the straight-line method over the estimated useful lives of the related assets. The useful lives of the assets are as follows: Computer equipment, 3 years.

Long-Lived and Intangible Assets

On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 827,670 common shares and 6,000,000 Series “A” Preferred Stock. These shares were valued at a total of $123,973. The Company has also paid additional funds to third parties to further the development of this asset and terminate the right of reversion totaling $45,000. The Company analyzed the assets at March 31, 2014 and determined that the value could not be supported and impaired the assets to $0.

On October 6, 2014, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Compositions and methods of use of Phorbol Esters for the treatment of Hodgkin’s Lymphoma”, and all related intellectual property, inventions and trade secrets, data and clinical study results. In consideration for the intellectual property the Company issued 2,207,920 common shares. These shares were valued at a total of $7,904,355; however, since the asset was acquired from a related party the Company valued the asset at the cost of the asset to the related party, $82,120, and treated the excess value as a deemed dividend reducing additional paid in capital. The Company analyzed the assets at March 31, 2015 and determined that the value could not be supported and impaired the assets to $0.

Fair Value of Financial Instruments

The Company’s financial instruments consist of cash and cash equivalents, prepaid expenses, accounts payable, accrued expenses, amounts due to related parties, stock deposits, and a convertible note payable. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements.

Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability. The guidance establishes three levels of inputs that may be used to measure fair value:

Level 1 – Observable inputs such as quoted prices in active markets;

Level 2 – Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly;

Level 3 – Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The Company did not have any level 1 or level 3 financial instruments at September 30, 2016 or March 31, 2016. As of September 30, 2016, the derivative liabilities were considered a level 2 item; see Note 8.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Income Taxes

Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.

Revenue Recognition

The Company will recognize revenue when products are fully delivered or services have been provided and collection is reasonably assured.

Research and Development

The Company will charge research and development costs to expense when incurred. The research and development costs include payments made to unrelated third party vendors for their work on enhancements to existing technology, or research into new potentially patentable products or processes.

Stock-Based Compensation

Stock-based compensation is accounted for at fair value in accordance with ASC Topic 718. On September 6, 2013, the Company approved the adoption of Rich Pharmaceuticals, Inc. 2013 Stock Option/Stock Issuance Plan (the "2013 Plan”). The 2013 Plan is intended to aid in recruiting and retaining key employees, directors or consultants and to motivate them by providing incentives through the granting of awards of stock options or other stock based awards. The 2013 Plan is administered by the board of directors. Directors, officers, employees and consultants and our affiliates are eligible to participate under the 2013 Plan. A total of 3,900,048 common shares have been reserved for awards under the 2013 Plan. During the year ended March 31, 2015, the Company granted 197,500 stock options to officers, directors, employees and consultants. During the period ended March 31, 2016, the Company granted 3,900,003 stock options to officers, directors, employees and consultants. The Company made the following modifications to the exercise prices of its options: January 12, 2015, the Company modified the exercise price on all outstanding stock options to $0.17; April 6, 2015, the Company modified the exercise price on all outstanding stock options to $0.08 per share; August 4, 2015, the Company modified the exercise price on all outstanding stock options to $0.01 per share.

Basic loss per share

The basic earnings (loss) per share is calculated by dividing the Company’s net income available to common shareholders by the weighted average number of common shares during the year. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity.

Recent Accounting Pronouncements

The Company does not expect the adoption of any other recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

XML

Property and equipment (Tables)

6 Months Ended

Sep. 30, 2016

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment

	September 30, 2016			March 31, 2016
Computer equipment & furniture	$	5,160		$	5,160
Less: accumulated depreciation		(2,291	)		(1,429	)
Property and equipment, net	$	2,869		$	3,731

XML

Accrued Expenses (Tables)

6 Months Ended

Sep. 30, 2016

Payables and Accruals [Abstract]

Schedule of Accrued Expenses

	September 30, 2016		March 31, 2016
Wages and taxes	$	703,756	$	514,713
Accrued interest		57,355		15,437
Total accrued expenses	$	761,111	$	530,150

XML

Equity Transactions (Tables)

6 Months Ended

Sep. 30, 2016

Accounting Policies [Abstract]

Schedule of Value of Warrants

Date	June 9, 2015	Dec 15,2015
Warrants	900,000	4,000,000
Stock price on grant date	$0.02	$0.01
Exercise price	$0.02	$0.01
Expected life	5 year	5 year
Volatility	98%	98%
Risk-free rate	1.74%	1.71%
Calculated value	$13,259	$29,612
Fair value allocation of proceeds	$13,259	$29,612

Schedule of Warrant Activity

	Number of warrants		Weighted average exercise price
Outstanding, March 31, 2016		4,930,666	$	0.192
Granted			$	—
Exercised		—		—
Outstanding, September 30, 2016		4,930,666	$	0.192

Schedule of Conversions of Common Stock

Date	Debt/Interest Converted	Common Stock Issued	Price per Share
April 1, 2015	$16,650	411,111	$0.04050
April 6, 2015	$10,000	209,644	$0.04770
April 8, 2015	$15,309	453,561	$0.03375
April 8, 2015	$20,001	454,545	$0.04400
April 9, 2015	$14,320	325,455	$0.04400
April 14, 2015	$10,000	236,967	$0.04220
April 16, 2015	$1,918	53,000	$0.03619
April 21, 2015	$10,000	259,740	$0.03850
April 29, 2015	$15,000	389,610	$0.03850
May 4, 2015	$5,083	131,464	$0.03866
May 12, 2015	$28,456	903,380	$0.03150
May 20, 2015	$20,199	947,645	$0.02131
May 20, 015	$17,240	783,636	$0.02200
May 27, 2015	$13,568	701,801	$0.01933
May 29, 2015	$15,000	882,353	$0.01700
June 11, 2015	$9,897	942,609	$0.01050
June 16, 2015	$14,100	1,175,000	$0.01200
June 16, 2015	$13,565	1,130,417	$0.01200
June 22, 2015	$7,415	1,235,833	$0.00600
June 22, 2015	$14,384	2,479,924	$0.00580
June 23, 2015	$7,752	1,292,000	$0.00600
September 16, 2015	$7,974	1,772,033	$0.00450
September 28, 2015	$10,000	1,666,667	$0.00600
September 29, 2015	$10,620	1,770,000	$0.00600
October 7, 2015	$2,250	375,000	$0.00600
October 7, 2015	$8,400	1,400,000	$0.00600
October 19, 2015	$9,720	1,620,000	$0.00600
November 2, 2015	$4,424	1,966,124	$0.00225
November 23, 2015	$10,000	1,666,667	$0.00600
November 30, 2015	$16,844	2,591,323	$0.00650
December 9, 2015	$1,746	775,991	$0.00225
December 17, 2015	$5,332	919,319	$0.00580
December 28, 2015	$1,341	596,200	$0.00225
December 28, 2015	$17,700	2,950,000	$0.00600
December 28, 2015	$14,305	2,384,167	$0.00600
December 28, 2015	$14,963	2,579,916	$0.00580
December 29, 2015	$8,395	1,399,167	$0.00600
December 29, 2015	$7,670	1,278,333	$0.00600
December 30, 2015	$6,651	2,956,248	$0.00225
January 1, 2016	$28,500	4,384,615	$0.00650
January 4, 2016	$19,339	3,223,213	$0.00600
January 5, 2016	$8,107	3,603,227	$0.00225
January 6, 2016	$16,070	2,678,333	$0.00600
January 6, 2016	$16,597	2,861,607	$0.00580
February 16 ,2016	$1,424	4,220,400	$0.00034
February 17, 2016	$12,800	8,443,272	$0.00152
February 23, 2016	$4,640	4,218,182	$0.00110
February 23, 2016	$3,086	4,200,871	$0.00073
February 24, 2016	$1,492	4,419,970	$0.00034
February 25, 2016	$3,000	2,638,987	$0.00114
February 25, 2016	$4,640	4,218,182	$0.00110
March 1, 2016	$1,313	5,834,458	$0.00022
March 2, 2016	$4,600	5,831,643	$0.00079
March 2, 2016	$1,650	2,586,410	$0.00064
March 2, 2016	$9,332	11,650,000	$0.00080
March 7, 2016	$2,799	6,546,292	$0.00043
March 11, 2016	$1,924	4,147,500	$0.00046
March 14, 2016	$2,245	7,125,777	$0.00032
March 15, 2016	$3,329	7,454,098	$0.00045
March 15, 2016	$5,210	11,450,000	$0.00046
March 22, 2016	$2,419	8,957,888	$0.00027
March 22, 2016	$2,367	7,200,486	$0.00033
March 22, 2016	$5,315	11,682,000	$0.00046
March 28, 2016	$1,986	8,958,779	$0.00022
March 31, 2016 Total	$602,376	194,603,040

Date	Debt/Interest Converted	Common Stock Issued	Price per Share
April 1, 2016	$2,197	9,766,311	$0.000225
April 4, 2016	$4,847	17,250,000	$0.000281
April 7, 2016	$1,750	9,722,222	$0.000180
April 14, 2016	$4,158	19,250,000	$0.000216
April 15, 2016	$1,318	9,766,222	$0.000135
April 26, 2016	$1,705	12,629,776	$0.000135
May 4, 2016	$2,067	9,718,025	$0.000213
May 31, 2016	$   828	4,600,055	$0.000180
June 2, 2016	$9,120	30,000,000	$0.000304
June 2, 2016	$4,401	29,340,333	$0.000150
June 14, 2016	$5,847	29,235,900	$.0.000200
June 17,2016	$5,691	28,456,150	$0.000200
June 29, 2016	$6,580	21,270,355	$0.000309
August 23, 2016	$2,567	22,129,741	$0.000116
August 29, 2016	$2,570	22,156,120	$0.000116
September 6, 2016	$2,547	21,952,672	$0.000116
September 20, 2016	$2,443	25,267,655	$0.000097
September 26, 2016	$2,946	25,393,448	$0.000116
September 28, 2016	$2,947	25,403,448	$0.000116
September 30, 2016	$3,949	51,066,724	$0.000077
September 30, 2016 Total	$70,478	424,375,157

Schedule of Value of Options

Date	April 6, 2015	June 9, 2015	December 15, 2015
Options	2,040,003	1,000,000	860,000
Stock price grant date	$0.08	$0.02	$0.01
Initial Exercise price	$0.08	$0.02	$0.01
Modified Exercise price	$0.01	$0.01	$0.01
Expected life	5.0	5.0	5.0
Volatility	99%	99%	84%
Risk-free rate	1.31%	1.74%	1.70%
Calculated value	$120,778	$14,838	$5,736
Modified value	$151,221	$16,347	$5,736

Schedule of Option Activity

	Number of options	Weighted average exercise price
Outstanding, March 31, 2015	672,533	$0.01
Granted	3,900,003	$0.01
Exercised	-	-
Expired	-	-
Outstanding, September 30, 2016	4,572,536	$0.01

XML

Summary of Significant Accounting Policies (Details Narrative)	3 Months Ended	6 Months Ended		12 Months Ended
	Sep. 30, 2015 shares	Sep. 30, 2016 USD ($) $ / shares shares	Sep. 30, 2015 shares	Mar. 31, 2016 USD ($) $ / shares shares	Mar. 31, 2015 shares	Mar. 31, 2014 shares	Mar. 31, 2013	Sep. 06, 2013 $ / shares shares	Sep. 05, 2013 $ / shares shares
Date Of Incorporation		Aug. 09, 2010
Common Stock, shares issued	14,690
Cancellation of loans | $
Common Stock, Shares Authorized		4,000,000,000		4,000,000,000				375,030,000	900,000
Common Stock, Par Value | $ / shares		$ .001		$ .001				$ 0.001	$ 0.001
Stock split ratio		0.01					4.1671
Cash and cash equivalent | $
Intangible assets | $		0
Impairment of intangible asset | $		$ 82,120
Reserved common shares		3,900,048
Stock options granted		3,900,003		197,500
Computer equipment		3 years
Options granted, number of shares			3,900,003	3,900,003	197,500	475,033
Options, exercise price | $ / shares		$ 0.001
Sale Agmt
Date of Agreement		Jul. 19, 2013
Cancellation of loans | $		$ 28,818
Shares sold by former officers		5,312,925
Shares returned to treasury		5,002,554
Shares agreed to cancel		2,625,210
Asset Assign Agmt
Date of Agreement		Jul. 18, 2013
Common Stock, shares issued		827,670
Series A Preferred Stock, shares issued		6,000,000
Stock Value | $		$ 123,973
Termination of agreement | $		20,000
Additional cash required | $		$ 2,000,000

XML

Property and equipment - Schedule of Property and Equipment (Details) - USD ($)	Sep. 30, 2016	Mar. 31, 2016
Property, Plant and Equipment [Abstract]
Computer equipment	$ 5,160	$ 5,160
Less: accumulated depreciation	(2,291)	(1,429)
Property and equipment, net	$ 2,869	$ 3,731

XML

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2016
Property And Equipment Details Narrative
Depreciation expense	$ 431	$ 118	$ 862	$ 237	$ 799
Computer equipment			3 years

XML

Intangible Assets (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended
	Sep. 30, 2015	Sep. 30, 2016
Common Stock, shares issued	14,690
Impairment of intangible asset		$ 82,120
Asset Assign Agmt
Date of Agreement		Jul. 18, 2013
Common Stock, shares issued		827,670
Series A Preferred Stock, shares issued		6,000,000
Stock Value		$ 123,973
Asset Assign Agmt #2
Date of Agreement		Oct. 06, 2014
Common Stock, shares issued		2,207,920
Common stock, value		$ 7,904,355
Impaired Assets		0
Impairment of intangible asset		$ 82,120

XML

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Sep. 30, 2016	Mar. 31, 2016
Payables and Accruals [Abstract]
Wages and taxes	$ 703,756	$ 514,713
Accrued interest	57,355	15,437
Total accrued expenses	$ 761,111	$ 530,150

XML

Related Party Debt and Transactions (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2016
Cancellation of loans
Due to related parties	$ 39,100		39,100				$ 76,913
Loans and interest received (repaid) from/to related parties			(37,812)	$ 30,417
Interest expense, related party	(155)	$ (150)	(230)	$ (224)
Accrued expenses	$ 761,111		$ 761,111				530,150
Sale Agmt
Date of Agreement			Jul. 19, 2013
Cancellation of loans			$ 28,818
CEO
Loan from related party					$ 5,000	$ 36,000
Repayment of loans to related parties					41,000
SH Loan #1
Loan from related party					$ 6,000
Interest Rate					8.00%
SH Loan #2
Loan from related party			$ 6,280
Interest Rate	8.00%		8.00%
Interest expense, related party			$ (597)
Related Party Loans
Repayment of loans to related parties			25,300
Accrued expenses	$ 3,100		3,100				$ 22,200
Accrued expenses, balance due
Employment Agmt
Date of Agreement			Sep. 06, 2013
Term of Agreement			2 years
Annual Compensation			$ 275,000
Options to purchase			30,002
Options to purchase, exercise price			$ 0.02
Bonus			$ 68,750
Earnings			137,500		$ 275,000
Accrued Earnings			$ 531,362		$ 395,630

XML

Note Payable (Details Narrative) - Note Payable #1	6 Months Ended
	Sep. 30, 2016 USD ($)
Date of Agreement	Aug. 13, 2014
Convertible Note	$ 900,000
Interest Rate	10.00%
Due Date	Aug. 01, 2017
Interest Accrued	$ 30,082

XML

Convertible Note Payable (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2016	Mar. 31, 2015
Debt Instrument, Converted Amount			$ 70,478	$ 308,451
Debt Instrument, Interest Accrued, Converted Amount			5,416
Common Stock, shares issued		14,690
Convertible Prom Note #6
Date of Agreement						Aug. 13, 2014
Convertible Note						$ 61,111
Interest Rate						12.00%
Due Date						Aug. 14, 2016
Interest Accrued			0			$ 1,067
Convertible Note, Balance						0
Original Issue Discount						5,500
Debt Instrument, Converted Amount						61,111
Debt Instrument, Interest Accrued, Converted Amount			$ 1,067			$ 6,266
Common Stock, shares issued			177,836			1,403,700
Convertible Prom Note #8
Date of Agreement						Sep. 18, 2014
Convertible Note						$ 64,500
Interest Rate						12.00%
Due Date						Sep. 18, 2015
Interest Accrued			$ 0			$ 8,240
Convertible Note, Balance			0			54,500
Original Issue Discount						5,500
Debt Instrument, Converted Amount			54,500			$ 10,000
Debt Instrument, Interest Accrued, Converted Amount			$ 8,240
Common Stock, shares issued			1,879,597			181,819
Convertible Prom Note #9
Date of Agreement						Sep. 23, 2014
Convertible Note						$ 55,000
Interest Rate						8.00%
Due Date						Jun. 23, 2015
Interest Accrued			$ 0			$ 2,158
Convertible Note, Balance			0			29,800
Debt Instrument, Converted Amount			29,800			$ 25,200
Debt Instrument, Interest Accrued, Converted Amount			$ 2,158
Common Stock, shares issued			864,672			700,000
Convertible Prom Note #10
Date of Agreement			Oct. 06, 2014
Convertible Note			$ 33,000
Interest Rate			8.00%
Due Date			Jul. 06, 2015
Interest Accrued			$ 0
Convertible Note, Balance			0
Debt Instrument, Converted Amount			33,000
Debt Instrument, Interest Accrued, Converted Amount			$ 1,320
Common Stock, shares issued			780,000
Convertible Prom Note #11
Date of Agreement			Nov. 06, 2014
Convertible Note			$ 55,000
Interest Rate			12.00%
Due Date			May 06, 2015
Interest Accrued			$ 0
Convertible Note, Balance			0
Debt Instrument, Converted Amount			55,000
Debt Instrument, Interest Accrued, Converted Amount			$ 3,553
Common Stock, shares issued			2,813,634
Convertible Prom Note #12
Date of Agreement			Nov. 25, 2014
Convertible Note			$ 43,000
Interest Rate			8.00%
Due Date			Aug. 28, 2015
Interest Accrued			$ 0
Convertible Note, Balance			0
Debt Instrument, Converted Amount			$ 46,510
Common Stock, shares issued			5,290,270
Fee			Default
Fee Amount					$ 3,510
Convertible Prom Note #13
Date of Agreement			Dec. 16, 2014
Convertible Note			$ 33,333
Interest Rate			12.00%
Due Date			Dec. 16, 2016
Interest Accrued			$ 0
Convertible Note, Balance			0
Original Issue Discount			3,333
Debt Instrument, Converted Amount			33,333
Debt Instrument, Interest Accrued, Converted Amount			$ 4,000
Common Stock, shares issued			5,047,167
Convertible Prom Note #14
Date of Agreement			Jan. 09, 2015
Convertible Note			$ 33,000
Interest Rate			8.00%
Due Date			Oct. 13, 2015
Interest Accrued			$ 0
Convertible Note, Balance			0
Debt Instrument, Interest Accrued, Converted Amount			$ 1,320
Common Stock, shares issued			8,470,000
Fee			Default
Fee Amount					16,500
Convertible Prom Note #15
Date of Agreement			Feb. 05, 2015
Convertible Note			$ 54,000
Interest Rate			8.00%
Due Date			Nov. 09, 2015
Interest Accrued			$ 5,579
Convertible Note, Balance			$ 47,980
Common Stock, shares issued			12,393,030
Fee			Default
Fee Amount					$ 27,000
Convertible Prom Note #16
Date of Agreement			Feb. 17, 2015
Convertible Note			$ 66,780
Interest Rate			8.00%
Due Date			Aug. 14, 2015
Interest Accrued			$ 0
Convertible Note, Balance			0
Original Issue Discount			6,780
Debt Instrument, Converted Amount			66,780
Debt Instrument, Interest Accrued, Converted Amount			$ 3,148
Common Stock, shares issued			8,854,031
Convertible Prom Note #17
Date of Agreement			Feb. 25, 2015
Convertible Note			$ 27,778
Interest Rate			12.00%
Due Date			Feb. 25, 2017
Interest Accrued			$ 0
Convertible Note, Balance			0
Debt Instrument, Converted Amount			27,778
Debt Instrument, Interest Accrued, Converted Amount			$ 3,333
Common Stock, shares issued			5,185,210
Convertible Prom Note #18
Date of Agreement					Mar. 09, 2015
Convertible Note					$ 55,000
Interest Rate					8.00%
Due Date	Jun. 23, 2017				Dec. 09, 2015
Interest Accrued	$ 0		$ 178		$ 0
Convertible Note, Balance	8,838				16,215
Debt Instrument, Converted Amount	7,377				38,785
Debt Instrument, Interest Accrued, Converted Amount	$ 422				$ 5,135
Common Stock, shares issued	46,484,586				57,733,852
Convertible Prom Note #19
Date of Agreement					Mar. 26, 2015
Convertible Note					$ 29,680
Interest Rate					8.00%
Due Date					Mar. 23, 2016
Interest Accrued			4,520		$ 2,577
Convertible Note, Balance					18,751
Original Issue Discount					1,680
Debt Instrument, Converted Amount					$ 10,929
Common Stock, shares issued					15,924,728
Convertible Prom Note #20
Date of Agreement						Mar. 02, 2015
Convertible Note						$ 58,300
Interest Rate						8.00%
Due Date						Aug. 14, 2015
Interest Accrued			0
Convertible Note, Balance			0			$ 1,898
Original Issue Discount						3,300
Debt Instrument, Converted Amount			1,898			$ 56,402
Debt Instrument, Interest Accrued, Converted Amount			$ 20
Common Stock, shares issued			53,000			1,215,551
Convertible Prom Note #21
Date of Agreement					May 05, 2015
Convertible Note					$ 68,900
Interest Rate					8.00%
Due Date					May 05, 2016
Interest Accrued			$ 3,951		$ 4,387
Convertible Note, Balance			34,500		60,439
Original Issue Discount					3,900
Original Issue Discount, unamortized					325
Debt Instrument, Converted Amount			25,939		8,461
Debt Instrument, Interest Accrued, Converted Amount			$ 2,675		$ 566
Common Stock, shares issued			224,358,188		18,135,267
Convertible Prom Note #22
Date of Agreement					May 06, 2015
Convertible Note					$ 10,500
Interest Rate					8.00%
Due Date					Feb. 08, 2016
Interest Accrued			$ 1,451		$ 1,133
Convertible Note, Balance					$ 15,750
Fee					Default
Fee Amount			$ 5,250
Convertible Prom Note #23
Date of Agreement			May 27, 2015
Convertible Note			$ 16,500
Interest Rate			8.00%
Due Date			May 28, 2016
Interest Accrued			$ 0
Convertible Note, Balance			0
Debt Instrument, Converted Amount			16,500
Debt Instrument, Interest Accrued, Converted Amount			$ 344
Common Stock, shares issued			2,591,323
Convertible Prom Note #24
Date of Agreement			Aug. 28, 2015
Convertible Note			$ 15,000
Interest Rate			8.00%
Due Date			Aug. 28, 2016
Interest Accrued			$ 0
Convertible Note, Balance			0
Debt Instrument, Converted Amount			15,000
Debt Instrument, Interest Accrued, Converted Amount			$ 939
Common Stock, shares issued			87,032,383
Convertible Prom Note #25
Date of Agreement			Sep. 04, 2015
Convertible Note			$ 19,000
Interest Rate			8.00%
Due Date			Jun. 04, 2016
Interest Accrued			$ 1,632
Convertible Note, Balance			$ 19,000
Convertible Prom Note #26
Date of Agreement					Dec. 29, 2015
Convertible Note					$ 57,378
Interest Rate					8.00%
Due Date			Jun. 23, 2017		Dec. 30, 2016
Interest Accrued			$ 51		$ 0
Convertible Note, Balance					1,609
Debt Instrument, Converted Amount					59,934
Debt Instrument, Interest Accrued, Converted Amount					$ 1,222
Common Stock, shares issued					35,927,887
Fee					Default
Fee Amount					$ 4,165
Convertible Prom Note #27
Date of Agreement			Jan. 22, 2016
Convertible Note			$ 60,500
Interest Rate			10.00%
Due Date			Oct. 22, 2016
Interest Accrued			$ 4,177
Convertible Prom Note #28
Date of Agreement			Feb. 25, 2016
Convertible Note			$ 27,500
Interest Rate			8.00%
Due Date			Feb. 25, 2017
Interest Accrued			$ 217
Convertible Note, Balance			10,755
Original Issue Discount, unamortized			836
Debt Instrument, Converted Amount			16,745
Debt Instrument, Interest Accrued, Converted Amount			$ 1,380
Common Stock, shares issued			66,500,000
Convertible Prom Note #29
Date of Agreement			Mar. 24, 2016
Convertible Note			$ 7,500
Interest Rate			8.00%
Due Date			Mar. 24, 2017
Interest Accrued			$ 312
Convertible Prom Note #34
Date of Agreement			May 25, 2016
Convertible Note			$ 30,000
Interest Rate			8.00%
Due Date			May 25, 2017
Interest Accrued			$ 842
Convertible Prom Note #30
Date of Agreement			Jun. 08, 2016
Convertible Note			$ 84,250
Interest Rate			8.00%
Due Date			Jun. 08, 2017
Interest Accrued			$ 2,105
Convertible Prom Note #32
Date of Agreement			Jun. 23, 2016
Convertible Note			$ 56,000
Interest Rate			8.00%
Due Date			Jun. 23, 2017
Interest Accrued			$ 1,215
Convertible Prom Note #35
Interest Accrued			$ 1,043

XML

Derivative Liabilities (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2016
Notes to Financial Statements
Change in value of derivative liability	$ (51,683)	$ (180,446)	$ (168,454)	$ (230,186)
Derivative expense		$ (142,073)		$ (335,244)
Debt Discount, Unamortized	16,005		16,005
Derivative liabilities	270,531		270,531		$ 446,912
Derivative liabilities

XML

Equity Transactions - Schedule of Value of Warrants (Details) - USD ($)	6 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Fair value allocation of proceeds		$ 13,259
Warrant #8
Date	Jun. 09, 2015
Warrants	$ 900,000
Stock price on grant date	$ 0.02
Exercise price	$ 0.02
Expected life	5 years
Volatility	98.00%
Risk-free rate	1.74%
Calculated value	$ 13,259
Fair value allocation of proceeds	$ 13,259
Warrant #9
Date	Dec. 15, 2015
Warrants	$ 4,000,000
Stock price on grant date	$ 0.01
Exercise price	$ 0.01
Expected life	5 years
Volatility	98.00%
Risk-free rate	1.71%
Calculated value	$ 29,612
Fair value allocation of proceeds	$ 29,612

XML

Equity Transactions - Schedule of Warrant Activity (Details) - $ / shares	6 Months Ended	12 Months Ended
	Sep. 30, 2016	Mar. 31, 2016
Accounting Policies [Abstract]
Beginning Balance, Issued Warrants	4,930,666
Beginning Balance, Average Exercise Price	$ 0.192
Issued, Warrants
Issued, Average Exercise Price
Exercised, Warrants
Exercised, Average Exercise Price
Expired Warrants
Expired Average Exercise Price
Ending Balance, Issued Warrants	4,930,666	4,930,666
Ending Balance, Average Exercise Price	$ 0.192	$ 0.192

XML

Equity Transactions - Schedule of Value of Options (Details)	6 Months Ended
	Sep. 30, 2016 USD ($) $ / shares shares
Stock Option 7
Date of Issuance	Apr. 06, 2015
Options | shares	2,040,003
Stock price on grant date	$ 0.08
Exercise price	0.08
Exercise price, modified	$ 0.01
Expected life	5 years
Volatility	99.00%
Risk-free rate	1.31%
Calculated value | $	$ 120,778
Modified value | $	$ 151,221
Stock Option 8
Date of Issuance	Jun. 09, 2015
Options | shares	1,000,000
Stock price on grant date	$ 0.02
Exercise price	0.02
Exercise price, modified	$ 0.01
Expected life	5 years
Volatility	99.00%
Risk-free rate	1.74%
Calculated value | $	$ 14,838
Modified value | $	$ 16,347
Stock Option 9
Date of Issuance	Dec. 15, 2015
Options | shares	860,000
Stock price on grant date	$ 0.01
Exercise price	0.01
Exercise price, modified	$ 0.01
Expected life	5 years
Volatility	84.00%
Risk-free rate	1.70%
Calculated value | $	$ 5,736
Modified value | $	$ 5,736

XML

Equity Transactions - Schedule of Option Activity (Details) - shares	6 Months Ended	12 Months Ended
	Sep. 30, 2015	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Accounting Policies [Abstract]
Beginning Balance, number of shares	672,533	672,533
Beginning Balance, weighted average exercise price	0.01	0.01
Options granted, number of shares	3,900,003	3,900,003	197,500	475,033
Options granted, weighted average exercise price
Options exercised, number of shares
Options exercised, weighted average exercise price
Options expired, number of shares
Options expired, weighted average exercise price
Ending Balance, number of shares		672,533	672,533
Ending Balance, weighted average exercise price		0.01	0.01

XML

Equity Transactions (Details Narrative)	3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 30, 2016 USD ($) $ / shares shares	Sep. 30, 2015 USD ($) shares	Sep. 30, 2016 USD ($) $ / shares shares	Sep. 30, 2015 USD ($) shares	Mar. 31, 2016 $ / shares shares	Mar. 31, 2015 shares	Mar. 31, 2014 shares	Mar. 31, 2013	Sep. 06, 2013 $ / shares shares	Sep. 05, 2013 $ / shares shares	Jul. 18, 2013 shares
Common Stock, Shares Authorized	4,000,000,000		4,000,000,000		4,000,000,000				375,030,000	900,000
Common Stock, Par Value | $ / shares	$ .001		$ .001		$ .001				$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	10,000,000		10,000,000		10,000,000
Preferred Stock, Par Value | $ / shares	$ .001		$ .001		$ .001
Series A Preferred Stock, Designated											6,000,000
Common Stock, Issued	640,739,418		640,739,418		216,364,262
Preferred Stock, Issued	6,000,000		6,000,000		6,000,000
Common Stock, shares issued		14,690
Stock split ratio			0.01					4.1671
Options granted, number of shares				3,900,003	3,900,003	197,500	475,033
Debt Instrument, Converted Amount | $			$ 70,478	$ 308,451
Stock-based compensation | $		$ 62,301		$ 192,392
Debt Conversion #26
Date of Issuance			Apr. 01, 2015
Common Stock, shares issued			411,111
Common Stock, price per share | $ / shares			$ 0.04050
Debt Instrument, Converted Amount | $			$ 16,650
Debt Conversion #27
Date of Issuance			Apr. 06, 2015
Common Stock, shares issued			209,644
Common Stock, price per share | $ / shares			$ 0.04770
Debt Instrument, Converted Amount | $			$ 10,000
Debt Conversion #28
Date of Issuance			Apr. 08, 2015
Common Stock, shares issued			453,561
Common Stock, price per share | $ / shares			$ 0.03375
Debt Instrument, Converted Amount | $			$ 15,309
Debt Conversion #29
Date of Issuance			Apr. 09, 2015
Common Stock, shares issued			325,455
Common Stock, price per share | $ / shares			$ 0.04400
Debt Instrument, Converted Amount | $			$ 14,320
Debt Conversion #30
Date of Issuance			Apr. 14, 2015
Common Stock, shares issued			236,967
Common Stock, price per share | $ / shares			$ 0.04220
Debt Instrument, Converted Amount | $			$ 10,000
Debt Conversion #31
Date of Issuance			Apr. 16, 2015
Common Stock, shares issued			53,000
Common Stock, price per share | $ / shares			$ 0.03619
Debt Instrument, Converted Amount | $			$ 1,918
Debt Conversion #32
Date of Issuance			Apr. 21, 2015
Common Stock, shares issued			259,740
Common Stock, price per share | $ / shares			$ 0.03850
Debt Instrument, Converted Amount | $			$ 10,000
Debt Conversion #33
Date of Issuance			Apr. 29, 2015
Common Stock, shares issued			389,610
Common Stock, price per share | $ / shares			$ 0.03850
Debt Instrument, Converted Amount | $			$ 15,000
Debt Conversion #34
Date of Issuance			May 04, 2015
Common Stock, shares issued			131,464
Common Stock, price per share | $ / shares			$ 0.03866
Debt Instrument, Converted Amount | $			$ 5,083
Debt Conversion #35
Date of Issuance			May 12, 2015
Common Stock, shares issued			903,380
Common Stock, price per share | $ / shares			$ 0.03150
Debt Instrument, Converted Amount | $			$ 28,456
Debt Conversion #36
Date of Issuance			May 20, 2015
Common Stock, shares issued			947,645
Common Stock, price per share | $ / shares			$ 0.02131
Debt Instrument, Converted Amount | $			$ 20,199
Debt Conversion #37
Date of Issuance			May 20, 2015
Common Stock, shares issued			783,636
Common Stock, price per share | $ / shares			$ 0.02200
Debt Instrument, Converted Amount | $			$ 17,240
Debt Conversion #38
Date of Issuance			May 27, 2015
Common Stock, shares issued			701,801
Common Stock, price per share | $ / shares			$ 0.01933
Debt Instrument, Converted Amount | $			$ 13,568
Debt Conversion #39
Date of Issuance			May 29, 2015
Common Stock, shares issued			882,353
Common Stock, price per share | $ / shares			$ 0.01700
Debt Instrument, Converted Amount | $			$ 15,000
Debt Conversion #40
Date of Issuance			Jun. 11, 2015
Common Stock, shares issued			942,609
Common Stock, price per share | $ / shares			$ 0.01050
Debt Instrument, Converted Amount | $			$ 9,897
Debt Conversion #41
Date of Issuance			Jun. 16, 2015
Common Stock, shares issued			1,175,000
Common Stock, price per share | $ / shares			$ 0.01200
Debt Instrument, Converted Amount | $			$ 14,100
Debt Conversion #42
Date of Issuance			Jun. 16, 2015
Common Stock, shares issued			1,130,417
Common Stock, price per share | $ / shares			$ 0.01200
Debt Instrument, Converted Amount | $			$ 13,565
Debt Conversion #43
Date of Issuance			Apr. 08, 2015
Common Stock, shares issued			454,545
Common Stock, price per share | $ / shares			$ 0.04400
Debt Instrument, Converted Amount | $			$ 20,001
Debt Conversion #44
Date of Issuance			Jun. 22, 2015
Common Stock, shares issued			1,235,833
Common Stock, price per share | $ / shares			$ 0.00600
Debt Instrument, Converted Amount | $			$ 7,415
Debt Conversion #45
Date of Issuance			Jun. 22, 2015
Common Stock, shares issued			2,479,924
Common Stock, price per share | $ / shares			$ 0.00580
Debt Instrument, Converted Amount | $			$ 14,384
Debt Conversion #46
Date of Issuance			Jun. 23, 2015
Common Stock, shares issued			1,292,000
Common Stock, price per share | $ / shares			$ 0.00600
Debt Instrument, Converted Amount | $			$ 7,752
Debt Conversion #47
Date of Issuance			Sep. 16, 2015
Common Stock, shares issued			1,772,033
Common Stock, price per share | $ / shares			$ 0.00450
Debt Instrument, Converted Amount | $			$ 7,974
Debt Conversion #48
Date of Issuance			Sep. 28, 2015
Common Stock, shares issued			1,666,667
Common Stock, price per share | $ / shares			$ 0.00600
Debt Instrument, Converted Amount | $			$ 10,000
Debt Conversion #49
Date of Issuance			Sep. 29, 2015
Common Stock, shares issued			1,770,000
Common Stock, price per share | $ / shares			$ 0.00600
Debt Instrument, Converted Amount | $			$ 10,620
Debt Conversion #50
Date of Issuance			Oct. 07, 2015
Common Stock, shares issued			375,000
Common Stock, price per share | $ / shares			$ 0.0060
Debt Instrument, Converted Amount | $			$ 2,250
Debt Conversion #51
Date of Issuance			Oct. 07, 2015
Common Stock, shares issued			1,400,000
Common Stock, price per share | $ / shares			$ 0.0060
Debt Instrument, Converted Amount | $			$ 8,400
Debt Conversion #52
Date of Issuance			Oct. 19, 2015
Common Stock, shares issued			1,620,000
Common Stock, price per share | $ / shares			$ 0.0060
Debt Instrument, Converted Amount | $			$ 9,720
Debt Conversion #53
Date of Issuance			Nov. 02, 2015
Common Stock, shares issued			1,966,124
Common Stock, price per share | $ / shares			$ 0.00225
Debt Instrument, Converted Amount | $			$ 4,424
Debt Conversion #54
Date of Issuance			Nov. 23, 2015
Common Stock, shares issued			1,666,667
Common Stock, price per share | $ / shares			$ 0.0060
Debt Instrument, Converted Amount | $			$ 10,000
Debt Conversion #55
Date of Issuance			Nov. 30, 2015
Common Stock, shares issued			2,591,323
Common Stock, price per share | $ / shares			$ 0.00650
Debt Instrument, Converted Amount | $			$ 16,844
Debt Conversion #56
Date of Issuance			Dec. 09, 2015
Common Stock, shares issued			775,991
Common Stock, price per share | $ / shares			$ 0.00225
Debt Instrument, Converted Amount | $			$ 1,746
Debt Conversion #57
Date of Issuance			Dec. 17, 2015
Common Stock, shares issued			919,319
Common Stock, price per share | $ / shares			$ 0.00580
Debt Instrument, Converted Amount | $			$ 5,332
Debt Conversion #58
Date of Issuance			Dec. 28, 2015
Common Stock, shares issued			596,200
Common Stock, price per share | $ / shares			$ 0.00225
Debt Instrument, Converted Amount | $			$ 1,341
Debt Conversion #59
Date of Issuance			Dec. 28, 2015
Common Stock, shares issued			2,950,000
Common Stock, price per share | $ / shares			$ 0.00600
Debt Instrument, Converted Amount | $			$ 17,700
Debt Conversion #60
Date of Issuance			Dec. 28, 2015
Common Stock, shares issued			2,384,167
Common Stock, price per share | $ / shares			$ 0.00600
Debt Instrument, Converted Amount | $			$ 14,305
Debt Conversion #61
Date of Issuance			Dec. 28, 2015
Common Stock, shares issued			2,579,916
Common Stock, price per share | $ / shares			$ 0.00580
Debt Instrument, Converted Amount | $			$ 14,963
Debt Conversion #62
Date of Issuance			Dec. 29, 2015
Common Stock, shares issued			1,399,167
Common Stock, price per share | $ / shares			$ 0.00600
Debt Instrument, Converted Amount | $			$ 8,395
Debt Conversion #63
Date of Issuance			Dec. 29, 2015
Common Stock, shares issued			1,278,333
Common Stock, price per share | $ / shares			$ 0.00600
Debt Instrument, Converted Amount | $			$ 7,670
Debt Conversion #64
Date of Issuance			Dec. 30, 2015
Common Stock, shares issued			2,956,248
Common Stock, price per share | $ / shares			$ 0.00225
Debt Instrument, Converted Amount | $			$ 6,651
2013 Stock Option Plan Amendment
Date of Agreement			Jan. 12, 2015
Options granted, number of shares			672,533
Exercise price | $ / shares			$ 0.17
Stock-based compensation | $			$ 50,448
2013 Stock Option Plan Amdt #2
Date of Agreement			Apr. 06, 2015
Options granted, number of shares			2,712,535
Exercise price | $ / shares			$ 0.08
Stock-based compensation | $			$ 9,316
2013 Stock Option Plan Amdt #3
Date of Agreement			Aug. 04, 2015
Options granted, number of shares			3,712,535
Exercise price | $ / shares			$ 0.02
Stock-based compensation | $			$ 47,463
Debt Conversion #65
Date of Issuance			Jan. 04, 2016
Common Stock, shares issued			3,223,213
Common Stock, price per share | $ / shares			$ 0.006
Debt Instrument, Converted Amount | $			$ 19,339
Debt Conversion #66
Date of Issuance			Jan. 05, 2016
Common Stock, shares issued			3,603,227
Common Stock, price per share | $ / shares			$ 0.00225
Debt Instrument, Converted Amount | $			$ 8,107
Debt Conversion #67
Date of Issuance			Jan. 06, 2016
Common Stock, shares issued			2,678,333
Common Stock, price per share | $ / shares			$ 0.006
Debt Instrument, Converted Amount | $			$ 16,070
Debt Conversion #68
Date of Issuance			Jan. 06, 2016
Common Stock, shares issued			2,861,607
Common Stock, price per share | $ / shares			$ 0.0058
Debt Instrument, Converted Amount | $			$ 16,597
Debt Conversion #69
Date of Issuance			Feb. 16, 2016
Common Stock, shares issued			4,220,400
Common Stock, price per share | $ / shares			$ 0.00034
Debt Instrument, Converted Amount | $			$ 1,424
Debt Conversion #70
Date of Issuance			Feb. 17, 2016
Common Stock, shares issued			8,443,272
Common Stock, price per share | $ / shares			$ 0.00152
Debt Instrument, Converted Amount | $			$ 12,800
Debt Conversion #71
Date of Issuance			Feb. 23, 2016
Common Stock, shares issued			4,218,182
Common Stock, price per share | $ / shares			$ 0.0011
Debt Instrument, Converted Amount | $			$ 4,640
Debt Conversion #72
Date of Issuance			Feb. 23, 2016
Common Stock, shares issued			4,200,871
Common Stock, price per share | $ / shares			$ 0.00073
Debt Instrument, Converted Amount | $			$ 3,086
Debt Conversion #73
Date of Issuance			Feb. 24, 2016
Common Stock, shares issued			4,419,970
Common Stock, price per share | $ / shares			$ 0.00034
Debt Instrument, Converted Amount | $			$ 1,492
Debt Conversion #74
Date of Issuance			Feb. 25, 2016
Common Stock, shares issued			2,638,987
Common Stock, price per share | $ / shares			$ 0.00114
Debt Instrument, Converted Amount | $			$ 3,000
Debt Conversion #75
Date of Issuance			Feb. 25, 2016
Common Stock, shares issued			4,218,182
Common Stock, price per share | $ / shares			$ 0.0011
Debt Instrument, Converted Amount | $			$ 4,640
Debt Conversion #76
Date of Issuance			Mar. 01, 2016
Common Stock, shares issued			5,834,458
Common Stock, price per share | $ / shares			$ 0.00022
Debt Instrument, Converted Amount | $			$ 1,313
Debt Conversion #77
Date of Issuance			Mar. 02, 2016
Common Stock, shares issued			5,831,642
Common Stock, price per share | $ / shares			$ 0.00079
Debt Instrument, Converted Amount | $			$ 4,600
Debt Conversion #78
Date of Issuance			Mar. 02, 2016
Common Stock, shares issued			2,586,410
Common Stock, price per share | $ / shares			$ 0.00064
Debt Instrument, Converted Amount | $			$ 1,650
Debt Conversion #79
Date of Issuance			Mar. 02, 2016
Common Stock, shares issued			11,650,000
Common Stock, price per share | $ / shares			$ 0.0008
Debt Instrument, Converted Amount | $			$ 9,332
Debt Conversion #80
Date of Issuance			Mar. 07, 2016
Common Stock, shares issued			6,546,292
Common Stock, price per share | $ / shares			$ 0.00043
Debt Instrument, Converted Amount | $			$ 2,799
Debt Conversion #81
Date of Issuance			Mar. 11, 2016
Common Stock, shares issued			4,147,500
Common Stock, price per share | $ / shares			$ 0.00046
Debt Instrument, Converted Amount | $			$ 1,924
Debt Conversion #82
Date of Issuance			Mar. 14, 2016
Common Stock, shares issued			7,125,777
Common Stock, price per share | $ / shares			$ 0.00032
Debt Instrument, Converted Amount | $			$ 2,245
Debt Conversion #83
Date of Issuance			Mar. 15, 2016
Common Stock, shares issued			7,454,098
Common Stock, price per share | $ / shares			$ 0.00045
Debt Instrument, Converted Amount | $			$ 3,329
Debt Conversion #84
Date of Issuance			Mar. 15, 2016
Common Stock, shares issued			11,450,000
Common Stock, price per share | $ / shares			$ 0.00046
Debt Instrument, Converted Amount | $			$ 5,210
Debt Conversion #85
Date of Issuance			Mar. 22, 2016
Common Stock, shares issued			8,957,888
Common Stock, price per share | $ / shares			$ 0.00027
Debt Instrument, Converted Amount | $			$ 2,419
Debt Conversion #86
Date of Issuance			Mar. 22, 2016
Common Stock, shares issued			7,200,486
Common Stock, price per share | $ / shares			$ 0.00033
Debt Instrument, Converted Amount | $			$ 2,367
Debt Conversion #87
Date of Issuance			Mar. 22, 2016
Common Stock, shares issued			11,682,000
Common Stock, price per share | $ / shares			$ 0.00046
Debt Instrument, Converted Amount | $			$ 5,315
Debt Conversion #88
Date of Issuance			Mar. 28, 2016
Common Stock, shares issued			8,958,779
Common Stock, price per share | $ / shares			$ 0.00022
Debt Instrument, Converted Amount | $			$ 1,986
Debt Conversion #89
Date of Issuance			Apr. 01, 2016
Common Stock, shares issued			9,766,311
Common Stock, price per share | $ / shares			$ 0.000225
Debt Instrument, Converted Amount | $			$ 2,197
Debt Conversion #90
Date of Issuance			Apr. 04, 2016
Common Stock, shares issued			17,250,000
Common Stock, price per share | $ / shares			$ 0.000281
Debt Instrument, Converted Amount | $			$ 4,847
Debt Conversion #91
Date of Issuance			Apr. 07, 2016
Common Stock, shares issued			9,722,222
Common Stock, price per share | $ / shares			$ 0.000180
Debt Instrument, Converted Amount | $			$ 1,750
Debt Conversion #92
Date of Issuance			Apr. 14, 2016
Common Stock, shares issued			19,250,000
Common Stock, price per share | $ / shares			$ 0.000216
Debt Instrument, Converted Amount | $			$ 4,158
Debt Conversion #93
Date of Issuance			Apr. 15, 2016
Common Stock, shares issued			9,766,222
Common Stock, price per share | $ / shares			$ 0.000135
Debt Instrument, Converted Amount | $			$ 1,318
Debt Conversion #94
Date of Issuance			Apr. 26, 2016
Common Stock, shares issued			12,629,776
Common Stock, price per share | $ / shares			$ 0.000135
Debt Instrument, Converted Amount | $			$ 1,705
Debt Conversion #95
Date of Issuance			May 04, 2016
Common Stock, shares issued			9,718,025
Common Stock, price per share | $ / shares			$ 0.000213
Debt Instrument, Converted Amount | $			$ 2,067
Debt Conversion #96
Date of Issuance			May 31, 2016
Common Stock, shares issued			4,600,055
Common Stock, price per share | $ / shares			$ 0.000180
Debt Instrument, Converted Amount | $			$ 828
Debt Conversion #97
Date of Issuance			Jun. 02, 2016
Common Stock, shares issued			30,000,000
Common Stock, price per share | $ / shares			$ 0.000304
Debt Instrument, Converted Amount | $			$ 9,120
Debt Conversion #98
Date of Issuance			Jun. 02, 2016
Common Stock, shares issued			29,340,333
Common Stock, price per share | $ / shares			$ 0.000150
Debt Instrument, Converted Amount | $			$ 4,401
Debt Conversion #99
Date of Issuance			Jun. 14, 2016
Common Stock, shares issued			29,235,900
Common Stock, price per share | $ / shares			$ 0.000200
Debt Instrument, Converted Amount | $			$ 5,847
Debt Conversion #100
Date of Issuance			Jun. 17, 2016
Common Stock, shares issued			28,456,150
Common Stock, price per share | $ / shares			$ 0.000200
Debt Instrument, Converted Amount | $			$ 5,691
Debt Conversion #101
Date of Issuance			Jun. 29, 2017
Common Stock, shares issued			21,270,355
Common Stock, price per share | $ / shares			$ 0.000309
Debt Instrument, Converted Amount | $			$ 6,580
Debt Conversion #102
Date of Issuance			Aug. 23, 2016
Common Stock, shares issued			22,129,741
Common Stock, price per share | $ / shares			$ 0.000116
Debt Instrument, Converted Amount | $			$ 2,567
Debt Conversion #103
Date of Issuance			Aug. 29, 2016
Common Stock, shares issued			22,156,120
Common Stock, price per share | $ / shares			$ 0.000116
Debt Instrument, Converted Amount | $			$ 2,570
Debt Conversion #104
Date of Issuance			Sep. 06, 2016
Common Stock, shares issued			21,952,672
Common Stock, price per share | $ / shares			$ 0.000116
Debt Instrument, Converted Amount | $			$ 2,547
Debt Conversion #105
Date of Issuance			Sep. 20, 2016
Common Stock, shares issued			25,267,355
Common Stock, price per share | $ / shares			$ 0.000097
Debt Instrument, Converted Amount | $			$ 2,443
Debt Conversion #106
Date of Issuance			Sep. 26, 2016
Common Stock, shares issued			25,393,447
Common Stock, price per share | $ / shares			$ 0.000116
Debt Instrument, Converted Amount | $			$ 2,946
Debt Conversion #107
Date of Issuance			Sep. 28, 2016
Common Stock, shares issued			25,403,448
Common Stock, price per share | $ / shares			$ 0.000116
Debt Instrument, Converted Amount | $			$ 2,947
Debt Conversion #108
Date of Issuance			Sep. 30, 2016
Common Stock, shares issued			51,066,724
Common Stock, price per share | $ / shares			$ 0.000077
Debt Instrument, Converted Amount | $			$ 3,949
Asset Assign Agmt
Date of Agreement			Jul. 18, 2015
Common Stock, shares issued			827,670
Series A Preferred Stock, shares issued			6,000,000
Shares Issued, Value | $			$ 123,973
Sale Agmt
Shares agreed to cancel			2,625,210
Shares returned to treasury			5,002,554
Date of Agreement			Jul. 19, 2013
Warrant #1
Exercise Date			Oct. 29, 2013
Warrants | $			$ 2,500
Stock price on grant date | $ / shares			$ 30.00
Exercise price | $ / shares			$ 50.00
Expected life			1 year
Warrant #2
Exercise Date			Dec. 11, 2013
Warrants | $			$ 2,500
Stock price on grant date | $ / shares			$ 30.00
Exercise price | $ / shares			$ 50.00
Expected life			1 year
Sale of Stock #1
Issuance of common stock for cash, shares			100,381
Issuance of common stock for cash, amount | $			$ 5,405
Date of Issuance			Apr. 22, 2015
Sale of Stock #2
Issuance of common stock for cash, shares			1,542,455
Issuance of common stock for cash, amount | $			$ 10,797
Date of Issuance			Jun. 25, 2015
Sale of Stock #3
Issuance of common stock for cash, shares			1,619,423
Issuance of common stock for cash, amount | $			$ 11,336
Date of Issuance			Jul. 07, 2015
Sale of Stock #4
Issuance of common stock for cash, shares			1,439,282
Issuance of common stock for cash, amount | $			$ 10,075
Date of Issuance			Jul. 15, 2015
Sale of Stock #5
Issuance of common stock for cash, shares			1,648,840
Issuance of common stock for cash, amount | $			$ 11,542
Date of Issuance			Oct. 27, 2015

XML

Commitments and Contingencies (Details Narrative)	Sep. 30, 2016 USD ($)
Accounting Policies [Abstract]
Monthly Rent	$ 2,800

XML

Subsequent Event (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2016	Sep. 06, 2013	Sep. 05, 2013
Common Stock, Shares Authorized			4,000,000,000		4,000,000,000	375,030,000	900,000
Debt Instrument, Converted Amount			$ 70,478	$ 308,451
Debt Instrument, Interest Accrued, Converted Amount			$ 5,416
Common Stock, shares issued		14,690
Debt Conversion #109
Date of Issuance	Oct. 07, 2016
Debt Instrument, Converted Amount	$ 3,035
Debt Instrument, Interest Accrued, Converted Amount	$ 346
Common Stock, shares issued	58,291,551
Debt Conversion #110
Date of Issuance	Oct. 14, 2016
Debt Instrument, Converted Amount	$ 3,030
Debt Instrument, Interest Accrued, Converted Amount	$ 350
Common Stock, shares issued	58,275,689
Debt Conversion #111
Date of Issuance	Oct. 21, 2016
Debt Instrument, Converted Amount	$ 3,033
Debt Instrument, Interest Accrued, Converted Amount	$ 355
Common Stock, shares issued	58,355,689
Debt Conversion #112
Date of Issuance	Oct. 26, 2016
Debt Instrument, Converted Amount	$ 3,025
Debt Instrument, Interest Accrued, Converted Amount	$ 358
Common Stock, shares issued	58,316,551
Debt Conversion #113
Date of Issuance	Nov. 07, 2016
Debt Instrument, Converted Amount	$ 5,015
Common Stock, shares issued	86,472,931
Convertible Prom Note #36
Date of Agreement	Oct. 20, 2016
Convertible Note	$ 58,000
Interest Rate	8.00%
Due Date	Oct. 20, 2017
Convertible Prom Note #37
Date of Agreement	Oct. 28, 2016
Convertible Note	$ 32,000
Interest Rate	8.00%
Due Date	Oct. 20, 2017